1. Scope and how to read this page
1.1 This page is the record behind the Weal Focus product page, the pouch, and the figures cited in the pieces published in the Weal Journal. Every figure and every claim that appears on the product page and on the pouch is set out below in the wording in which it is printed, and the Journal figures are set out at section 10 in the terms in which they are stated, together with the evidence each rests on, the reason it is worded as it is, and the limitations of that evidence. The wordings on the product page are settled. The function of this page is to record what each one rests on — not to restate any of them in softer language, and not to present a claim here in terms different from the terms in which it is sold.
1.2 Clauses in sections 2 to 10 each carry four numbered parts: .1 the statement at issue, quoted as it appears on the site where the site prints a wording and described where it does not; .2 the evidence, cited in full; .3 the reasoning for the wording; and .4 the limitations. Sections 1 and 11 are procedural. They record no claim about the product or its ingredients, so they carry no evidence, reasoning or limitation part, and none is implied by their absence.
1.3 Weal Focus, the finished product, has never been the subject of a trial. Every trial cited on this page tested a single ingredient, or — in the clauses at section 5 — L-theanine together with caffeine, which is not an ingredient of this product; each at a dose and in a population named in the clause that cites it. No published research has measured what happens when alpha-GPC, lion's mane, L-theanine, zinc and vitamin B12 are taken together in the amounts declared on the pouch, and no published research has measured the experience of a person who purchases and takes this product. Where a statement on the site describes an outcome for such a person, the limitation part of the governing clause says so.
1.4 These are structure/function statements within the meaning of section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act and 21 CFR 101.93(f), which permits a label or labelling to bear statements describing the role of a nutrient or dietary ingredient intended to affect the structure or function of the body, or characterising the documented mechanism by which it acts to maintain that structure or function. They are not disease claims within the meaning of 21 CFR 101.93(g), and nothing on this page or on the product page should be read as one. A statement of this kind carries obligations under the regulation: notification to the Food and Drug Administration, a certification that the firm holds substantiation for the statement, and the disclaimer printed at the close of this page. Two clauses below rest in part on health claims authorised in the European Union under Commission Regulation (EU) No 432/2012. Those authorisations have no force in the United States, where the same sentences are structure/function statements; the clauses say which is which.
1.5 Where the figure printed on the site is rounder, larger, or more confident than the figure in its source, the limitation part of the clause says so and gives the source figure. Several clauses below do. A limitation is not softened here to protect a wording; where the evidence does not reach as far as the sentence, the clause says how far it reaches.
1.6 Where a source could not be read in full — because it is a subscription document, or because the publisher's host would not return the text to us — the clause says so and says what was read instead: an abstract, a bibliographic record, or an archived copy of the page. A source that could not be opened is not treated as a source that says nothing, and a source cited on its record rather than on a passage read is identified as such in the clause that cites it.
1.7 Citations are printed in full, with permanent identifiers — a digital object identifier, a PubMed identifier, a regulation citation, a bookshelf identifier or a report number — rather than as links, so that each can be retrieved independently of this page and of us. Internal documents, being unpublished, carry a description and, where one exists, a reference number instead. Amounts are given as the source gives them; where the arithmetic is ours rather than the source's, the clause says so. Statements are quoted as they stood in September 2026.
2. Alpha-GPC
2.1.1 Statement. The first bullet in the buy box reads: “Alpha-GPC was clinically shown to more than double attention test gains versus the next best option.”
2.1.2 Evidence. Kerksick CM (2024), Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men, Nutrients 16(23):4240; DOI 10.3390/nu16234240; PMID 39683633; PMCID PMC11644786. A randomised, double-blind, placebo-controlled crossover conducted at the Center for Applied Health Sciences, Canfield, Ohio. Twenty-one healthy resistance-trained men aged 20 to 55 with at least two years' training experience were recruited; all analyses report twenty (mean age 31.3, SD 11.0), and the paper states no reason for the difference. Three single-dose conditions were tested: a resistant-dextrin placebo, 315 mg of alpha-GPC, and 630 mg, with study visits approximately four to seven days apart. A cognitive battery of Stroop, Flanker and N-Back was run 60 minutes after ingestion and again 30 minutes after a lower-body resistance-exercise bout. The paper reports that the Stroop total score increased to a statistically significantly greater degree on 630 mg (13.0 ± 8.2; p = 0.013; d = 0.61) and on 315 mg (10.8 ± 7.7; p = 0.046; d = 0.48) than on placebo (5.2 ± 9.0). Dividing 10.8 by 5.2 gives 2.08, and 13.0 by 5.2 gives 2.50; that division is ours. The trial is registered as NCT06690619. Funding was provided by Nanjing Nutrabuilding Bio-tech (NNB Nutrition) through a restricted grant, and the paper states that its author serves as a paid scientific advisor to the sponsor.
2.1.3 Reasoning. The arithmetic behind “more than double” is exact and traceable to a published, placebo-controlled trial: the change score on the 315 mg arm is 2.08 times the change score on placebo. The phrase is the strongest true framing the published change scores will carry, and it was chosen in preference to a percentage of improvement, which the site does not print for this or any ingredient.
2.1.4 Limitations. “The next best option” was an inert placebo capsule, not a rival ingredient or a competing product. A reader who follows the number to the paper finds a placebo, and the phrase invites a comparison the trial did not make. No alpha-GPC trial has out-performed another choline source on an attention test in healthy adults. The two alpha-GPC trials that did contain an active comparator — 200 mg of caffeine, in Parker 2015 and Marcus 2017, both cited at clause 2.3.2 — found no significant cognitive separation at all. “Clinically shown” rests on a single crossover in twenty men, funded by the maker of the alpha-GPC used and authored by a paid advisor to that sponsor. The registry lists Stroop, Flanker and N-Back as three co-primary cognitive outcomes; only one separated from placebo, at an uncorrected p = 0.046, and the paper concedes that “using more rigorous correction for pairwise comparisons may have impacted our final outcomes”. Registration was filed in November 2024 for a study completed in June 2024 — retrospective by five months — so the primary outcome was not publicly pre-specified.
2.2.1 Statement. The first tile of the numbers block reads: “10.8 — points gained on a standardised attention test with about 300 mg of Alpha-GPC — over double the next best option.” The block is introduced by the heading “See the research behind Weal Focus.”
2.2.2 Evidence. Kerksick 2024, cited in full at clause 2.1.2. The 315 mg arm produced a Stroop total score change of 10.8 ± 7.7 (p = 0.046 against placebo; d = 0.48); placebo produced 5.2 ± 9.0 over the identical window; the 630 mg arm produced 13.0 ± 8.2 (p = 0.013; d = 0.61). The table footnote defines these as delta scores: “All values are reported and analyzed as delta scores (30 min post-exercise–60 min post-ingestion).” Stroop time required per score improved significantly on the high dose only (−0.12 ± 0.09 s against −0.05 ± 0.09 s; p = 0.021; d = 0.56); on 315 mg it was a non-significant trend (−0.10 ± 0.08 s; p = 0.072). Registry record NCT06690619 (sponsor Lindenwood University, collaborator NNB Nutrition) gives actual enrolment 20, study start 9 January 2024, primary completion and completion 11 June 2024, first submitted 12 November 2024.
2.2.3 Reasoning. The tile prints a raw point count rather than a percentage because a point count is the figure the paper actually reports, is checkable against it without conversion, and cannot be mistaken for a promised improvement in a purchaser. “About 300 mg” is a fair description of a 315 mg dose; the product is 4.8 per cent below the amount studied.
2.2.4 Limitations. Placebo gained 5.2 of those 10.8 points on the same measurement window, so the share attributable to alpha-GPC is 5.6 points, not 10.8, and a single numeral cannot carry its own comparator. The window is not what “points gained with about 300 mg” suggests: it is the change between a reading taken 60 minutes after the dose and a reading taken 30 minutes after a resistance-exercise bout, in trained men measured mid-session, not a before-and-after of taking a capsule at a desk. The placebo standard deviation (± 9.0) is larger than the placebo mean (5.2), so the ratio of 2.08 is a quotient of two small and noisy numbers and would move a long way on a few participants. The block itself names no study; this clause is where the study is named. The remaining limitations at clause 2.1.4 — comparator, sponsorship, multiplicity and retrospective registration — apply to this tile in full.
2.3.1 Statement. Two wordings are live. The Benefits tab reads: “In recent trials, similar doses lifted scores on a standardised attention test almost twice as well as the next best option.” The alpha-GPC ingredient card reads: “In recent trials, similar doses lifted scores on standardised tests over twice as well as the next best option.”
2.3.2 Evidence. The ratio comes from Kerksick 2024 alone, cited at clause 2.1.2: 10.8 ± 7.7 on 315 mg and 13.0 ± 8.2 on 630 mg against 5.2 ± 9.0 on placebo. Those are two dose arms of one crossover, not two trials, and the comparator is placebo. The other two standardised tests in the same battery, Flanker and N-Back, showed no significant difference. The other published alpha-GPC studies with cognitive endpoints in healthy adults are: Parker AG, Byars A, Purpura M, Jäger R (2015), The effects of alpha-glycerylphosphorylcholine, caffeine or placebo on markers of mood, cognitive function, power, speed, and agility, Journal of the International Society of Sports Nutrition 12(Suppl 1):P41; DOI 10.1186/1550-2783-12-S1-P41; PMCID PMC4595381 (no PubMed identifier assigned) — a conference proceedings abstract, open access in full, randomised double-blind placebo-controlled crossover, twenty participants (ten male, ten female; 22.0 ± 3.4 years), four conditions of 200 mg alpha-GPC, 400 mg alpha-GPC, 200 mg caffeine and placebo, measured 30 minutes after supplementation, supported by Chemi Nutra, concluding: “Acute supplementation with caffeine or Alpha-GPC had no statistically significant beneficial effect on measures of mood, cognitive function, or physiological performance, in part due to large individual variability between subjects.” And Marcus L, Soileau J, Judge LW, Bellar D (2017), Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance, Journal of the International Society of Sports Nutrition 14:39; DOI 10.1186/s12970-017-0196-5; PMID 29042830; PMCID PMC5629791 — a double-blind four-arm randomised trial in forty-eight healthy college-aged males, twelve per arm, taking 500 mg alpha-GPC, 250 mg alpha-GPC, 200 mg caffeine or placebo daily for seven days, partially funded by a research grant from Chemi Nutra, which reports of the psychomotor vigilance task that “the analysis did not reveal any significant differences by group (p > 0.5)” for mean reaction time, maximum reaction time and minor lapses in attention.
2.3.3 Reasoning. Both wordings sit in running prose rather than beside a citation, and the plural framing was chosen so that the sentence would read as a description of the research rather than as an isolated statistic. The two live wordings differ in strength; of the two, “almost twice” is the more conservative reading of a ratio of 2.08.
2.3.4 Limitations. The plural is not supported. Exactly one trial has produced this ratio. The two other alpha-GPC studies with cognitive endpoints in healthy adults — one at a dose close to ours — found no significant cognitive benefit, and both are also the only alpha-GPC studies containing an actual alternative to compare against, in each case 200 mg of caffeine, from which alpha-GPC did not separate. “Standardised tests” is likewise plural where, within the one supporting trial, two of the three standardised tests in the battery were null. The sentences therefore read as though a body of recent research converges on a doubling, when the published record is one positive industry-funded result and two null results, and no trial has compared alpha-GPC against a next-best option on an attention test in healthy people.
2.4.1 Statement. The Benefits tab reads: “Alpha-GPC is the form we chose because it is the highest quality form of choline.” The ingredient card reads: “Alpha-GPC is the highest quality form of choline.”
2.4.2 Evidence. Health Canada (2024), Summary of Health Canada's safety assessment of L-alpha-glycerylphosphorylcholine for use as a supplemental ingredient, Food Directorate (page date modified 2 May 2024), states the conversion ratio as 1 mg of alpha-GPC to 0.4 mg of choline, that “AGPC is cleaved in the gut into choline and glycerol-1-phosphate”, and that “the main circulating metabolite after ingestion is choline; intact AGPC was not detected in the plasma”; it records human data up to 1,200 mg a day for up to six months. Che X, Zhao Y, Xu Z, Hu Y, Ren A, Wu C, Yang J (2025), Unlocking the Potential of l-α-Glycerylphosphorylcholine: From Metabolic Pathways to Therapeutic Applications, Nutrition Reviews 83(8):1594–1620; PMID 40036805; DOI 10.1093/nutrit/nuaf008, describes alpha-GPC as the precursor “not only of choline and acetylcholine but also of various phospholipids” (abstract read; the full text is subscription-gated and was not read). By standard molecular weights, choline bitartrate is about 41 per cent choline and choline chloride about 75 per cent; that arithmetic is ours, not a statement in any source cited here.
2.4.3 Reasoning. “Highest quality” describes a purchasing and formulation decision rather than a measured ranking: it delivers choline on a glycerophosphate backbone, and it is several times the cost of the bulk choline salts it is chosen over. The same phrase is used about each ingredient in the formula and is governed collectively by clause 9.3.
2.4.4 Limitations. No published measurement establishes alpha-GPC as superior to another choline form for any purpose in healthy adults, so “highest quality” cannot be read as a ranking on an outcome. The weight-for-weight claim circulated in the trade — that alpha-GPC carries more choline per milligram than the alternatives — is wrong: at about 40 per cent choline it sits marginally below choline bitartrate and far below choline chloride. Clause 2.5.4 sets out what the only human head-to-head of absorption found.
2.5.1 Statement. The first of the six items headed “Here is what Alpha-GPC does once it is inside you” reads in part: “Thankfully, Alpha-GPC is the form of choline that is most readily absorbed by your body.”
2.5.2 Evidence. Böckmann KA, Franz AR, Minarski M, Shunova A, Maiwald CA, Schwarz J, Gross M, Poets CF, Bernhard W (2022), Differential metabolism of choline supplements in adult volunteers, European Journal of Nutrition 61(1):219–230; PMID 34287673; DOI 10.1007/s00394-021-02637-6; PMCID PMC8783899. A prospective randomised four-way crossover in six healthy men aged 31 to 64 (median 37), each given a single oral dose of 550 mg choline equivalent as choline chloride, choline bitartrate, alpha-GPC or egg phosphatidylcholine at least a week apart, with plasma sampled by tandem mass spectrometry from before the dose to six hours and again at twenty-four hours. It is the only published human head-to-head of oral alpha-GPC against other choline forms at a matched choline dose, and it reports: “There was no difference between the area under the curve (AUC) at 0–24 h and 0–6 h for choline plasma concentrations after administration of the four different supplements.” Median plasma choline area under the curve over the first six hours was 61.6 µmol/L·h for alpha-GPC against 63.4 for choline chloride, 66.4 for choline bitartrate and 67.9 for egg phosphatidylcholine — alpha-GPC numerically the lowest of the four. Peak rise was approximately +6 µmol/L for all four; median time to peak was 1.75 hours for alpha-GPC. The study was investigator-initiated and partly funded by a research grant from an infant-formula manufacturer. The superlative's usual source is Gatti G, Barzaghi N, Acuto G, Abbiati G, Fossati T, Perucca E (1992), A comparative study of free plasma choline levels following intramuscular administration of L-alpha-glycerylphosphorylcholine and citicoline in normal volunteers, International Journal of Clinical Pharmacology, Therapy and Toxicology 30(9):331–335; PMID 1428296 — twelve volunteers, 1,000 mg of each compound given by intramuscular injection, in which alpha-GPC produced “a rapid rise in plasma choline, peak levels being usually observed at the first (0.25 h) or second (0.5 h) sampling time after the injection”, with citicoline “considerably lower”.
2.5.3 Reasoning. The sentence is the shortest available answer to the question a buyer asks when comparing this product with an inexpensive tub of choline bitartrate, and the belief it states is widespread in the category and has a real study behind it.
2.5.4 Limitations. The superlative is not supported, and the best available evidence points the other way. The one oral head-to-head in humans found no difference in plasma choline between alpha-GPC and three other forms, with alpha-GPC numerically lowest over the first six hours. The study that does favour alpha-GPC administered it by intramuscular injection, which bypasses the intestinal mucosa and the portal circulation entirely and therefore reports nothing about absorption from the gut, and at a dose more than three times the amount in this product. Böckmann is six men and part-funded by industry, so it is thin evidence of equivalence; but thin evidence of no difference is the best evidence there is, and it does not support a ranking. What the evidence does support is a statement about form and timing rather than rank: alpha-GPC delivers choline together with a glycerophosphate backbone and peaks at about 1.75 hours.
2.6.1 Statement. The same item reads: “Alpha-GPC has to get past the gut and the liver before it is sent to your brain.”
2.6.2 Evidence. Health Canada (2024), cited at clause 2.4.2: alpha-GPC “is cleaved in the gut into choline and glycerol-1-phosphate”, and “the main circulating metabolite after ingestion is choline; intact AGPC was not detected in the plasma”. Abbiati G, Fossati T, Lachmann G, Bergamaschi M, Castiglioni C (1993), Absorption, tissue distribution and excretion of radiolabelled compounds in rats after administration of [14C]-L-alpha-glycerylphosphorylcholine, European Journal of Drug Metabolism and Pharmacokinetics 18(2):173–180; PMID 8243501; DOI 10.1007/BF03188793, the primary absorption and distribution study, reports that “it is assumed that alpha-GPC is hydrolyzed by phosphodiesterases in the gut mucosa”, and that radioactivity was “particularly concentrated in the liver, kidney, lung and spleen compared to blood”. Böckmann 2022, cited at clause 2.5.2, additionally documents that gut bacteria take a share of an oral choline dose before absorption: all the water-soluble supplements, alpha-GPC included, rapidly increased plasma trimethylamine-N-oxide, whereas egg phosphatidylcholine did not.
2.6.3 Reasoning. The item introduces the journey an oral dose makes before any of it reaches the brain, and the physiology is correct in direction: everything absorbed from the gut drains into the portal vein and passes the liver first, and the liver is where the radiolabel concentrates most in the animal distribution study.
2.6.4 Limitations. The subject of the sentence is wrong. Alpha-GPC does not get past the gut: it is cleaved in the gut wall, and intact alpha-GPC is not detectable in plasma. What passes the gut and the liver is ordinary free choline, the same molecule any choline source yields. If the sentence is read as an argument that alpha-GPC survives this journey better than other forms, no human data support it, and the trimethylamine-N-oxide result shows that alpha-GPC is subject to the same pre-absorptive bacterial degradation as the cheaper salts.
2.7.1 Statement. The alpha-GPC ingredient card opens: “Choline in the form that reaches the brain, where it becomes acetylcholine — the messenger that holds your attention on one thing.”
2.7.2 Evidence. Health Canada (2024), cited at clause 2.4.2, states that intact alpha-GPC is not detected in plasma and that the main circulating metabolite is choline, while also recording that “AGPC oral administration results in an increase of plasma choline levels and acetylcholine levels in neurons of the hippocampus and cerebral cortex”. Abbiati 1993, cited at clause 2.6.2, reports that brain concentrations of the label were “comparable to … or lower than … total blood radioactivity”, that “the metabolite profile in the perfused brain showed a small amount of choline and two unknown metabolites”, and that “choline was incorporated into brain phospholipids in increasing amounts within 24 h of dosing”. Sigala S, Imperato A, Rizzonelli P, Casolini P, Missale C, Spano P (1992), L-alpha-glycerylphosphorylcholine antagonizes scopolamine-induced amnesia and enhances hippocampal cholinergic transmission in the rat, European Journal of Pharmacology 211(3):351–358; PMID 1319912; DOI 10.1016/0014-2999(92)90392-h, reports that oral alpha-GPC prevented scopolamine-induced amnesia “dose-dependent with a maximum at 300 mg/kg”, that it “dose dependently increased ACh release with a maximum at 300 mg/kg”, and that intravenous labelled alpha-GPC resulted in labelled acetylcholine formation. Tan J, Bluml S, Hoang T, Dubowitz D, Mevenkamp G, Ross B (1998), Lack of effect of oral choline supplement on the concentrations of choline metabolites in human brain, Magnetic Resonance in Medicine 39(6):1005–1010; PMID 9621925; DOI 10.1002/mrm.1910390619, reports that in four brain locations “no significant increases in Cho/Cr, [Cho], or in its major constituents were found in response to an oral challenge of 50 mg/kg of choline bitartrate”.
2.7.3 Reasoning. The card opens with the destination rather than the chemistry because the reader needs to know in one line why a choline compound is in a focus product. The downstream step it compresses is real in the animal record: choline from alpha-GPC is incorporated into brain phospholipid and converted to hippocampal acetylcholine.
2.7.4 Limitations. Read literally the phrase is not accurate: the form that reaches the brain is free choline, not alpha-GPC, and the definite article implies a uniqueness no choline source can hold, since every oral source yields the same free choline. The supporting neurochemistry is from rats, at 300 mg per kilogram of body weight — by body-surface-area conversion roughly 3,400 mg for a 70 kg adult, about eleven times the amount in this product and nearly three times the ceiling of the human safety evidence; that conversion is ours. No human imaging study has shown any oral choline form raising brain choline acutely; the one that looked, at a large dose of choline bitartrate, found nothing.
2.8.1 Statement. The frequently-asked questions read: “Most products use choline bitartrate because it is inexpensive. Alpha-GPC is the form of choline your body absorbs most readily, and in a placebo-controlled trial in healthy men it raised the free choline in the blood within two hours of the first dose.”
2.8.2 Evidence. Marcus 2017, cited in full at clause 2.3.2. Blood was drawn at 60 and 120 minutes after the first dose. The paper reports: “Analysis of serum free choline via repeated measures ANOVA resulted in a significant difference by treatment (F = 14.98 p = 0.001) but not for a treatment by time (1 h, 2 h) interaction (F = 0.196, p = 0.928). The caffeine and placebo treatment had the lowest free choline levels respectively, with the 250 mg A-GPC and 500 mg A-GPC demonstrating significantly higher levels.” The timing is independently corroborated, outside the alpha-GPC trade, by Böckmann 2022, cited at clause 2.5.2, in which median time to peak plasma choline after oral alpha-GPC was 1.75 hours. Kerksick 2024 is sometimes cited for blood choline and should not be: that trial measured no plasma or serum choline at all, drawing blood for growth hormone only.
2.8.3 Reasoning. The second half of the sentence names a real placebo-controlled measurement rather than resting the comparison on assertion, and “within two hours of the first dose” is a fair description of draws at 60 and 120 minutes, corroborated by an independent time-to-peak of 1.75 hours.
2.8.4 Limitations. The sentence joins a sourced clause to an unsourced one, and the sourced clause lends credibility the first has not earned: Marcus 2017 contains no comparator choline form, only placebo and caffeine, so it cannot vouch for “absorbs most readily”, and a reader will naturally take it as doing so. The trial is a parallel-group design part-funded by an alpha-GPC supplier, and its two published free-choline results are not dose-ordered — the smaller dose produced the larger rise — so the size of the effect is not usable. The doses tested were 250 mg and 500 mg; the product contains 300 mg, inside that bracket but not tested at it. Clause 2.5.4 governs the superlative.
2.9.1 Statement. The second item reads: “Inside a nerve cell, an enzyme joins choline to an acetyl group to make acetylcholine, the messenger that holds attention on one thing and carries signal from one nerve to the next.”
2.9.2 Evidence. Oda Y (1999), Choline acetyltransferase: the structure, distribution and pathologic changes in the central nervous system, Pathology International 49(11):921–937; PMID 10594838; DOI 10.1046/j.1440-1827.1999.00977.x, describes choline acetyltransferase as “the enzyme responsible for the biosynthesis of acetylcholine” and “the most specific indicator for monitoring the functional state of cholinergic neurones”. Zeisel SH, da Costa KA (2009), Choline: an essential nutrient for public health, Nutrition Reviews 67(11):615–623; PMID 19906248; DOI 10.1111/j.1753-4887.2009.00246.x; PMCID PMC2782876, records that choline is needed for neurotransmitter synthesis, membrane signalling, lipid transport and methyl-group metabolism. Picciotto MR, Higley MJ, Mineur YS (2012), Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior, Neuron 76(1):116–129; PMID 23040810; DOI 10.1016/j.neuron.2012.08.036; PMCID PMC3466476, characterises acetylcholine as a neuromodulator that “alters neuronal excitability, influences synaptic transmission, induces synaptic plasticity, and coordinates firing of groups of neurons”, notes that “the mode of cholinergic transmission has remained controversial”, that “accumulating evidence indicates that ACh can act through volume transmission in the brain”, and that “there is an anatomical mismatch between the sites of ACh release and the location of cholinergic receptors”.
2.9.3 Reasoning. The enzyme is not named on the product page because the name costs a reader more than it conveys; the item states the reaction in plain words, and the reaction as stated is textbook.
2.9.4 Limitations. The final clause is a compression. In the cortex and the hippocampus the dominant mode of cholinergic action is neuromodulation, and whether acetylcholine there acts through classical point-to-point synapses or through volume transmission is unsettled, with a documented mismatch between where it is released and where its receptors sit. Acetylcholine is a classical transmitter that carries signal from one nerve to the next at the neuromuscular junction and in autonomic ganglia, which is not the attention system the item is describing. “Holds attention on one thing” summarises a body of lesion and microdialysis work rather than any single measurement.
2.10.1 Statement. The third item reads: “The nerve cells that run from the base of the forebrain into the hippocampus and the cortex are the ones that work when you hold a thread through a meeting or keep your place in a long piece of reading.”
2.10.2 Evidence. Ballinger EC, Ananth M, Talmage DA, Role LW (2016), Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline, Neuron 91(6):1199–1218; PMID 27657448; DOI 10.1016/j.neuron.2016.09.006; PMCID PMC5036520, identifies the basal forebrain nuclei as “the major sources of cholinergic projection neurons to neocortex, hippocampus and amygdala”, with the hippocampus and entorhinal cortex receiving the majority of their cholinergic input from the medial septal and vertical diagonal band groups. Kozak R, Bruno JP, Sarter M (2006), Augmented prefrontal acetylcholine release during challenged attentional performance, Cerebral Cortex 16(1):9–17; PMID 15788700; DOI 10.1093/cercor/bhi079, reports in rats that attentional performance was associated with a 140 per cent increase in acetylcholine efflux in medial prefrontal cortex. Craft TK, Mahoney JH, Devries AC, Sarter M (2005), Microsphere embolism-induced cortical cholinergic deafferentation and impairments in attentional performance, European Journal of Neuroscience 21(11):3117–3132; PMID 15978021; DOI 10.1111/j.1460-9568.2005.04136.x, reports in rats that loss of cortical cholinergic fibre density produced a specific decrease in the ability to detect signals, with residual fibre density correlating with attentional performance.
2.10.3 Reasoning. The anatomy is correct and well established, and the two everyday scenes are offered as illustrations of sustained attention, which is the function the underlying work measures.
2.10.4 Limitations. Every quantitative result behind the functional half is from rats. No human study has shown that these neurons are “the ones that work” while a person follows a meeting or keeps their place in a long read; the two scenes are ours, not any study's endpoint. The same basal forebrain population is also the major cholinergic input to the amygdala, so naming only the hippocampus and the cortex is a selective cut, and the attention findings are specifically prefrontal and frontoparietal rather than cortical at large.
2.11.1 Statement. The fourth item reads: “Caffeine blocks adenosine, the molecule that signals tiredness. It adds nothing to the attention system itself, and its effect fades as your tolerance builds. Choline, on the other hand, supplies the material that system is built from. The two do different jobs, which is why they go so well together in the morning.”
2.11.2 Evidence. Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE (1999), Actions of caffeine in the brain with special reference to factors that contribute to its widespread use, Pharmacological Reviews 51(1):83–133; PMID 10049999; DOI 10.1016/s0031-6997(24)01396-6, is the standard reference for caffeine acting at habitual human doses as an adenosine-receptor antagonist. The paper carries no abstract and its full text is behind a paywall that would not return to us; it is cited here on its record and its standing in the field, and no statement on this page rests on it alone. Porkka-Heiskanen T, Strecker RE, Thakkar M, Bjorkum AA, Greene RW, McCarley RW (1997), Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness, Science 276(5316):1265–1268; PMID 9157887; DOI 10.1126/science.276.5316.1265, reports in cats that extracellular adenosine in the basal forebrain cholinergic region rises through sustained wakefulness and declines in recovery sleep, and that the sleep-deprivation profile was reproduced by raising adenosine in the cholinergic basal forebrain but not in a control non-cholinergic region. Carter AJ, O'Connor WT, Carter MJ, Ungerstedt U (1995), Caffeine enhances acetylcholine release in the hippocampus in vivo by a selective interaction with adenosine A1 receptors, Journal of Pharmacology and Experimental Therapeutics 273(2):637–642; PMID 7752065, reports in rats that oral caffeine dose-dependently increased extracellular hippocampal acetylcholine, an effect blocked by tetrodotoxin and counteracted by an A1 agonist. Rogers PJ, Hohoff C, Heatherley SV, Mullings EL, Maxfield PJ, Evershed RP, Deckert J, Nutt DJ (2010), Association of the anxiogenic and alerting effects of caffeine with ADORA2A and ADORA1 polymorphisms and habitual level of caffeine consumption, Neuropsychopharmacology 35(9):1973–1983; PMID 20520601; DOI 10.1038/npp.2010.71; PMCID PMC3055635, a randomised double-blind parallel-groups trial in 379 adults, reports that “caffeine did not increase alertness in NL participants” and concludes that with frequent consumption “no net benefit for alertness is gained, as caffeine abstinence reduces alertness and consumption merely returns it to baseline”.
2.11.3 Reasoning. The item exists to explain why a choline product and a cup of coffee are complementary rather than competing, and two of its three assertions are well founded: caffeine's mechanism is adenosine-receptor antagonism, and tolerance to its alerting effect is documented in a good human trial.
2.11.4 Limitations. Caffeine blocks adenosine receptors; it does not block adenosine. The middle assertion — that caffeine adds nothing to the attention system itself — is contradicted by the evidence on the very system the surrounding items describe: adenosine's sleep-promoting action is exerted specifically in the basal forebrain cholinergic region, and caffeine raises hippocampal acetylcholine release by blocking A1 receptors there. Both of those results are from animals, so the contradiction rests on animal mechanism rather than human data, and the paper cited for caffeine's receptor pharmacology is one we could not read in full. The tolerance clause understates its source in one direction and overstates it in another: the trial found no net alertness benefit in regular consumers, a withdrawal-reversal reading that remains contested, while caffeine does reliably improve vigilance in acutely dosed or overnight-abstinent people. A distinction of kind — that caffeine lifts a brake on alertness while choline supplies material the cholinergic system is built from — is what the evidence supports.
2.12.1 Statement. The fifth item reads: “Most of the choline in your body is built into phosphatidylcholine, the main ingredient in the membrane of every cell you have. Nerve cells depend on those membranes to keep their shape and hold the machinery they signal with.”
2.12.2 Evidence. Zeisel and da Costa 2009, cited at clause 2.9.2: “The major fate of choline is conversion to PC (also known as lecithin), which occurs in all nucleated cells,” and “PC is the predominant phospholipid (>50%) in most mammalian membranes.” van Meer G, Voelker DR, Feigenson GW (2008), Membrane lipids: where they are and how they behave, Nature Reviews Molecular Cell Biology 9(2):112–124; PMID 18216768; DOI 10.1038/nrm2330; PMCID PMC2642958: “PtdCho accounts for >50% of the phospholipids in most eukaryotic membranes.” Corbin KD, Zeisel SH (2012), Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression, Current Opinion in Gastroenterology 28(2):159–165; PMID 22134222; DOI 10.1097/MOG.0b013e32834e7b4b; PMCID PMC3601486: “The two major fates for choline are to be phosphorylated and used to make phospholipids, or to be oxidized and used as a donor of methyl-groups.”
2.12.3 Reasoning. The first half is accurate without qualification, and the item exists to explain why choline matters structurally as well as as a transmitter precursor.
2.12.4 Limitations. The second half is rounder than its sources in two specific ways. Phosphatidylcholine is more than half of the phospholipid, not of the membrane: membranes also carry cholesterol and sphingolipids, and dropping the word “phospholipid” is what makes the figure stop being true. And “every cell you have” is not what the sources say — both write “most” membranes, and there are exceptions within the body, including the inner mitochondrial membrane and mature red blood cells, which the careful phrase “all nucleated cells” quietly excludes. “The most abundant phospholipid in your cell membranes” is what the sources will carry.
2.13.1 Statement. The sixth item reads: “Choline from Alpha-GPC also supports liver health and fat metabolism. Your liver uses choline to package fats into the particles that carry them around the body, and a steady supply keeps that normal process running.” (wording changed 2026-09-22; the clause below was written against the earlier sentence, “Alpha-GPC also moves fat out of your liver…”, and its evidence and limitations apply unchanged)
2.13.2 Evidence. Corbin and Zeisel 2012, cited at clause 2.12.2: “An especially important choline metabolite in liver is phosphatidylcholine, which is necessary for the packaging and export of triglycerides in very low density lipoprotein (VLDL) and for the solubilization of bile salts for secretion,” and “humans eating low-choline diets develop fatty liver and liver damage.” Fischer LM, daCosta KA, Kwock L, Stewart PW, Lu TS, Stabler SP, Allen RH, Zeisel SH (2007), Sex and menopausal status influence human dietary requirements for the nutrient choline, American Journal of Clinical Nutrition 85(5):1275–1285; PMID 17490963; DOI 10.1093/ajcn/85.5.1275; PMCID PMC2435503 — a controlled feeding study in fifty-seven adults given 550 mg of choline per 70 kg a day for ten days and then under 50 mg for up to forty-two days — reports that on the depletion diet 77 per cent of men and 80 per cent of postmenopausal women developed fatty liver or muscle damage, against 44 per cent of premenopausal women, with organ function restored when choline was added back. Zeisel SH, Da Costa KA, Franklin PD, Alexander EA, Lamont JT, Sheard NF, Beiser A (1991), Choline, an essential nutrient for humans, FASEB Journal 5(7):2093–2098; PMID 2010061, reports the liver-enzyme changes on which the choline Adequate Intake was later set. Lee G, Choi S, Chang J, Choi D, Son JS, Kim K, Kim SM, Jeong S, Park SM (2021), Association of L-α Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years, JAMA Network Open 4(11):e2136008; PMID 34817582; DOI 10.1001/jamanetworkopen.2021.36008; PMCID PMC8613599 — a population-based retrospective cohort of 12,008,977 Korean adults aged 50 and over, of whom 108,877 were prescribed alpha-GPC — reports a higher ten-year risk of total stroke in matched users (adjusted hazard ratio 1.43; 95% confidence interval 1.41–1.46), with a dose-response relationship by prescription duration.
2.13.3 Reasoning. The second sentence is close to a paraphrase of the published mechanism and rests on good human data; the item is included because choline's best-evidenced role in humans is hepatic rather than cognitive, and omitting it would misrepresent what the nutrient does.
2.13.4 Limitations. The first sentence has no evidence behind it for alpha-GPC specifically. A search of the published literature for alpha-GPC together with the liver, hepatic function or steatosis returns twelve records, and not one tests alpha-GPC on liver fat or on the export of triglyceride. The entire chain runs on choline, and the bridge from alpha-GPC to it is inference from composition, not measurement. The human studies describe what happens when choline is deficient under experimental depletion; they do not show that adding choline to a person who already has enough exports more liver fat. At 300 mg, alpha-GPC yields roughly 123 mg of choline, well under the Adequate Intake, so it is a partial contribution to intake rather than a corrective dose. The observational stroke association above is attached to this exact ingredient, at pharmaceutical doses in a prescribed population aged 50 and over, and cannot establish cause — but it is the most serious signal in the alpha-GPC record and it is set down here rather than omitted. Finally, a sentence phrased as something the capsule does to a reader's liver sits at the boundary between a structure/function statement and an implied disease claim, and is the one item on the product page where that boundary is close.
3. Choline intake
3.1.1 Statement. The Benefits tab and the alpha-GPC ingredient card both read: “About 9 in 10 American adults get less choline from food than the adequate intake.”
3.1.2 Evidence. Wallace TC, Fulgoni VL 3rd (2016), Assessment of Total Choline Intakes in the United States, Journal of the American College of Nutrition 35(2):108–112; DOI 10.1080/07315724.2015.1080127; PMID 26886842 — a cross-sectional analysis of the National Health and Nutrition Examination Survey 2009–2012, 16,809 participants aged two and over, usual intakes estimated by the National Cancer Institute method from 24-hour dietary recalls, choline from foods only — reports that among adults aged nineteen and over, 6.6 ± 0.5 per cent achieved the Adequate Intake, so 93.4 per cent fell below it. Wallace TC, Fulgoni VL (2017), Usual Choline Intakes Are Associated with Egg and Protein Food Consumption in the United States, Nutrients 9(8):839; DOI 10.3390/nu9080839; PMID 28783055; PMCID PMC5579632, on the 2009–2014 cycles, reports that “only 8.03 ± 0.56% of adults … meet the [Adequate Intake] for choline”, so 91.97 per cent do not. Independently, Ilayan A, Dustin D, Kowalski C, Belury MA, Johnson LK, Conrad Z (2025), Micronutrient Inadequacy Differs by Intake of Fat Amount and Class Among Adults That Consume a Restricted Carbohydrate Diet: National Health and Nutrition Examination Survey, 2007-2018, Journal of the Academy of Nutrition and Dietetics 125(4):501–514.e1; DOI 10.1016/j.jand.2024.11.001; PMID 39521380, in 15,029 adults aged twenty and over, reports that 5.6 per cent of adults meeting the Acceptable Macronutrient Distribution Ranges exceeded the Adequate Intake for choline. The reference value is set by the Institute of Medicine (1998), Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline, Chapter 12, National Academies Press; Bookshelf NBK114308; ISBN 978-0-309-06411-8: 550 mg a day for adult men and 425 mg for adult women. The National Institutes of Health Office of Dietary Supplements fact sheet on choline for health professionals records average intakes from foods and beverages of 402 mg in men and 278 mg in women, states that “most people in the United States consume less than the [Adequate Intake] for choline”, and that “intakes from supplements contribute a very small amount to total choline intakes”; the live page would not return to us and was read in an Internet Archive capture of 14 September 2026.
3.1.3 Reasoning. “About 9 in 10” is the honest floor of a range that runs from 92 to 94 per cent for adults, and a round fraction is read where a decimal is skipped. The two qualifiers are load-bearing and deliberate: “from food” is accurate, because every source that produces this figure excludes supplements, and “less than the adequate intake” stops at a descriptive fact rather than asserting deficiency.
3.1.4 Limitations. Falling below the Adequate Intake is not the same as being deficient, and the Adequate Intake was not set on a cognitive endpoint. The adult value was derived from a single feeding study in which 500 mg a day prevented liver-enzyme abnormalities in healthy men, and the Institute of Medicine chapter states that the estimate “is uncertain because it is based on a single published study”. An Adequate Intake is not an Estimated Average Requirement, so the proportion of a population below it cannot be read as a prevalence of inadequacy; the authors of the most-cited analysis say so themselves. The Office of Dietary Supplements adds that “frank choline deficiency in healthy men and nonpregnant women is very rare, possibly because of the contribution of choline that the body synthesizes endogenously”. The two most-cited papers share the same pair of authors, and the conflict-of-interest section of the 2017 paper discloses academic consulting and writing fees from Balchem Corporation, a current academic consultancy for the Egg Nutrition Center, a competitive research grant from the National Cattleman’s Beef Association, and, for the second author, analyses of the National Health and Nutrition Examination Survey conducted for numerous members of the food and beverage industry; that does not affect the arithmetic, which a separate research group replicated in the same band with no such ties, but a careful reader should know it. Finally, the sentence sits one clause away from a trial-efficacy statement, and none of these sources supports the chain a reader may complete from the one to the other.
3.2.1 Statement. The second tile of the numbers block reads: “9 in 10 — American adults get less choline from food than the adequate intake.”
3.2.2 Evidence. As at clause 3.1.2. The closest published match to this wording and scope is Wallace and Fulgoni 2017, in which 8.03 ± 0.56 per cent of adults meet the Adequate Intake from food alone.
3.2.3 Reasoning. The tile carries its scope inside its own label — “from food” and “than the adequate intake” are both printed — which is unusual discipline for a figure set in large type, and the number chosen is the conservative end of the published range, so a reader who checks finds the site understated rather than overstated.
3.2.4 Limitations. The tile drops the hedge that the ingredient cards keep: the cards say “about 9 in 10”, the tile says “9 in 10”. It has no room to say which survey, which years, or that the benchmark was derived from a liver marker, and the block itself names no study. Some articles that carry this figure attach it to sources that do not support it nationally; clauses 10.1 and 10.2 set out what those two papers actually report and why neither is the primary source for a national statement.
3.3.1 Statement. The Benefits tab reads: “Attention runs on acetylcholine, and your brain builds acetylcholine out of choline.”
3.3.2 Evidence. Hasselmo ME, Sarter M (2011), Modes and models of forebrain cholinergic neuromodulation of cognition, Neuropsychopharmacology 36(1):52–73; DOI 10.1038/npp.2010.104; PMID 20668433; PMCID PMC2992803: “As indicated by the profound cognitive impairments caused by cholinergic receptor antagonists, cholinergic neurotransmission has a vital role in cognitive function, specifically attention and memory encoding,” with changes in cholinergic modulation on a timescale of seconds serving “to facilitate cue detection and attentional performance”. The Office of Dietary Supplements fact sheet on choline states that “choline is needed to produce acetylcholine, an important neurotransmitter for memory, mood, muscle control, and other brain and nervous system functions”. Ojiakor OA, Rylett RJ (2020), Modulation of sodium-coupled choline transporter CHT function in health and disease, Neurochemistry International 140:104810; DOI 10.1016/j.neuint.2020.104810; PMID 32768485, reports that reuptake of choline from the synaptic cleft by the high-affinity choline transporter “is the rate-limiting step for production of ACh”.
3.3.3 Reasoning. The sentence is mechanism rather than efficacy: it exists to make the following clause about alpha-GPC mean something to a reader who has not encountered choline, and it makes no claim about what the product does to anyone.
3.3.4 Limitations. The second half is textbook and uncontested. The first half is a compression: acetylcholine modulates attention, gating cue detection and sharpening signal against noise, but attention is not powered by it as a machine is by fuel, and noradrenaline and dopamine are as load-bearing in the same circuits. Placing the two halves together does not license the chain a reader may complete — more dietary choline, therefore more acetylcholine, therefore better attention. The rate-limiting step for acetylcholine synthesis is synaptic reuptake rather than dietary supply; the federal fact sheet’s summary of the cognitive evidence is hedged, noting a 2015 systematic review of thirteen studies that found choline supplements did not produce clear improvements in cognition in healthy adults; and none of these sources tests alpha-GPC at any dose.
4. Lion's mane
4.1.1 Statement. The Benefits tab reads: “Lion's mane, 400 mg, fruiting body. This is the patient one. It supports maintaining normal cognitive function and is in the pouch for the long run.” The ingredient card reads: “It supports normal cognitive function and is here for the long run rather than the first morning.”
4.1.2 Evidence. Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T (2009), Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial, Phytotherapy Research 23(3):367–372; DOI 10.1002/ptr.2634; PMID 18844328 — thirty Japanese men and women aged 50 to 80 diagnosed with mild cognitive impairment, randomised into two groups of fifteen, taking 3.0 g a day of tablets containing 96 per cent dried Yamabushitake powder for sixteen weeks, with four weeks of observation afterwards — reports significantly increased scores on a cognitive function scale based on the Revised Hasegawa Dementia Scale at weeks 8, 12 and 16, scores increasing with duration of intake, and a significant decrease four weeks after intake stopped. The first author's affiliation is the laboratory of a mushroom producer. Saitsu Y, Nishide A, Kikushima K, Shimizu K, Ohnuki K (2019), Improvement of cognitive functions by oral intake of Hericium erinaceus, Biomedical Research (Tokyo) 40(4):125–131; DOI 10.2220/biomedres.40.125; PMID 31413233 — thirty-four enrolled and thirty-one analysed, all healthy and over fifty, taking 3.2 g a day of powdered fruiting body for twelve weeks — reports a significant between-group difference at the twelve-week endpoint on the Mini-Mental State Examination total (p = 0.0328), with an age-adjusted group-by-time interaction of p = 0.029, and no significant effect on either of the other two cognitive instruments. Docherty S, Doughty FL, Smith EF (2023), The Acute and Chronic Effects of Lion's Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults: A Double-Blind, Parallel Groups, Pilot Study, Nutrients 15(22):4842; DOI 10.3390/nu15224842; PMID 38004235; PMCID PMC10675414 — forty-one healthy adults aged 18 to 45, 1.8 g — reports faster Stroop performance sixty minutes after a single dose (p = 0.005) and, after twenty-eight days, only a trend toward reduced subjective stress (p = 0.051), stating that “null and limited negative findings were also observed” and that the findings “should be interpreted with caution”. Surendran G and colleagues (2025), Frontiers in Nutrition 12:1405796; PMID 40276537 — eighteen healthy adults aged 18 to 35 given 3 g of a 10:1 fruiting-body extract in a cross-over design — found no significant effect on composite cognition or mood at ninety minutes. The permitted form of words is set by 21 CFR 101.93(f), which allows statements describing the role of a dietary ingredient in affecting the structure or function of the body, provided they are not disease claims under 101.93(g).
4.1.3 Reasoning. The wording is a vocabulary formula rather than a finding, and that is deliberate: it describes a role, names no disease and promises no measurable change. “For the long run rather than the first morning” is the honest reading of the chronic data — the supporting effect in the sixteen-week trial grew with duration and fell back after intake stopped, while the acute trials are near-null — and it sets a purchaser's expectation against, rather than with, the pattern that would sell a first-morning effect.
4.1.4 Limitations. The dose gap is the whole limitation. The two trials that carry the wording used about 2.9 g a day of dried powder for sixteen weeks in people aged 50 to 80 with diagnosed mild cognitive impairment, and 3.2 g a day of fruiting-body powder for twelve weeks in healthy adults over fifty. Our amount is 400 mg, seven to eight times smaller by weight. The bridge offered by the ingredient specification is an eight-to-one extract ratio, which would make 400 mg equivalent to 3.2 g of raw material; that ratio is not verified by the laboratory report described in clause 9.5, and an extract ratio is not in any case a validated equivalence of effect, since hot-water extraction concentrates beta-glucans while the compounds the trial authors credit are not what a beta-glucan assay measures. The supporting effects are small: the significant endpoint difference in the twelve-week trial was a fraction of a point on a thirty-point screening instrument on which both groups finished close to the ceiling, and two of its three cognitive instruments found nothing. The populations run the other way from the wording: the trials with positive chronic results are in adults over fifty, one of them with diagnosed impairment — which is precisely why the word on the page is “normal”, since a claim about restoring impaired function would be a disease claim — while the two acute trials are in adults aged 18 to 45 and 18 to 35 and are null or near-null. Clause 4.3 records why no efficacy figure for this ingredient appears anywhere on the site.
4.2.1 Statement. The Benefits tab reads: “We use 100% fruiting bodies, not mycelium grown on grain, standardised to at least 25% beta-glucans — in other words, you are receiving the highest quality lion's mane out there.” The ingredient card reads: “The mushroom itself, not mycelium grown on grain and milled in with it, standardised to at least 25% beta-glucans — the mushroom's own structural compounds.”
4.2.2 Evidence. The fruiting-body requirement and the beta-glucan floor are terms of our purchasing specification, which requires at least 25 per cent beta-glucans by enzymatic assay and not a “polysaccharide” figure. The distinction the specification draws is real and documented. McCleary BV, Draga A (2016), Measurement of β-Glucan in Mushrooms and Mycelial Products, Journal of AOAC International 99(2):364–373; DOI 10.5740/jaoacint.15-0289; PMID 26957216, establishes that total glucan is measured by controlled acid hydrolysis with glucose oxidase detection, that alpha-glucan — starch and glycogen — is measured separately and subtracted, and that assays based wholly on enzymatic hydrolysis “in general, yielded much lower values”; a beta-glucan percentage therefore means something only if grain starch has been subtracted out, and a “polysaccharide” percentage, which is what most mushroom labels print, cannot distinguish mushroom beta-glucan from substrate starch. Windsor C, Kreynes AE, Chilton JS, Chioffi WA, Krishnamurthy A, Ishii M (2025), Comparative Study of Chaga (Inonotus obliquus) Dietary Supplements Using Complementary Analytical Techniques, International Journal of Molecular Sciences 26(7):2970; DOI 10.3390/ijms26072970; PMID 40243601; PMCID PMC11988691, reports that “β-Glucan quantification and iodine-starch assays confirmed starch-rich composition in fermented grains and its absence in authentic chaga canker”; the study is of chaga rather than lion's mane, and five of its six authors are employed by a fruiting-body raw-material supplier with a commercial interest in the distinction, the sixth by a testing laboratory that supplier uses, both disclosed in the paper.
4.2.3 Reasoning. Naming beta-glucans rather than “polysaccharides”, and excluding mycelium grown on grain, is a meaningful and checkable distinction rather than category noise.
4.2.4 Limitations. What is printed is what we buy to: the specification names the fruiting body, the extract ratio and the beta-glucan floor, and the pouch prints them. “At least 25 per cent” is a floor rather than a measured value for any one lot, and the assay route bears on how stringent a floor it is, since the lower-yielding enzymatic methods systematically under-read. The fruiting-body choice is a composition and purity decision rather than a proven advantage in effect: the longest chronic human trial of this mushroom used erinacine-A-enriched mycelium (Li IC and colleagues, 2020, Frontiers in Aging Neuroscience 12:155; PMID 32581767) at 1,050 mg a day across a forty-nine-week treatment period in patients with mild Alzheimer's disease — a population and a claim we make no use of. The superlative in “the highest quality lion's mane out there” is governed by clause 9.3.
4.3.1 Statement. No efficacy figure for lion's mane appears anywhere on the product page, in the numbers block, or in any of our published writing. This clause records why.
4.3.2 Evidence. The trials set out at clause 4.1.2. Their doses run from four and a half to eight times the amount in this product; the positive chronic results are in adults over fifty, one group with diagnosed impairment; the significant endpoint result in the healthy-adult trial is a fraction of a point on a thirty-point instrument on which both groups finished close to the ceiling; and the two trials in younger healthy adults are near-null — one faster Stroop result among many measures in the first, and no significant effect on composite cognition or mood in the second.
4.3.3 Reasoning. A figure this dose cannot carry would be worse than no figure. Printing a trial result next to 400 mg would invite a reader to attribute that result to this amount, which no evidence supports, so the ingredient is described by its role and its time-course only.
4.3.4 Limitations. The absence of a figure is not evidence of an effect at 400 mg. Lion's mane is in the formula on the strength of a permitted structure/function role, a purity specification, and the pattern of the chronic trials, not on a measured result at the amount we use.
4.4.1 Statement. Two wordings are governed together by this clause: the Benefits tab's “Think of it as a foundation from which the formula builds on top of”, and the Month 3 line of the six-month timeline, “Lion's mane and the other ingredients continue to provide a strong foundation from which Alpha-GPC builds.”
4.4.2 Evidence. There is none for the relationship asserted. A search of the PubMed index in September 2026 for lion's mane together with alpha-GPC, choline alfoscerate or glycerylphosphorylcholine returned no records: no human trial has tested these two ingredients together, in this formula or any other. The mechanistic story that makes the wording sound reasonable exists only in cell culture and rodents, and via compounds our label neither measures nor prints: Ma BJ, Shen JW, Yu HY, Ruan Y, Wu TT, Zhao X (2010), Hericenones and erinacines: stimulators of nerve growth factor (NGF) biosynthesis in Hericium erinaceus, Mycology 1(2):92–98; DOI 10.1080/21501201003735556, records that hericenones are isolated from fruiting bodies and erinacines from mycelium, that both stimulate nerve growth factor synthesis in vitro, and that neither class is what a beta-glucan assay measures. 21 CFR 101.93(f) shelters a statement characterising “the documented mechanism” by which an ingredient acts; no document exists for this one.
4.4.3 Reasoning. The wording gives a second ingredient a role in the formula's story without claiming a measurable result for it, and it is consistent with the time-course difference between the ingredients recorded at clauses 4.1 and 8.2.
4.4.4 Limitations. The relationship is not supported. Nothing establishes that one ingredient in this formula is a foundation for another, and the word “strong” asserts as fact about a purchaser's third month a proposition no study has tested. Because the Month 3 wording sits on a timeline, it reads as a claim about the sequence and timing of effects, and no research supports a three-month foundation-laying phase at 400 mg — a dose no trial has tested. Unlike the wording at clause 4.1.1, this is not a recognised structure/function form of words and it has no documented mechanism behind it. It is properly read as a description of how the formula was designed rather than as a description of what is happening in a person taking it.
5. L-theanine
5.1.1 Statement. The ingredient card reads: “The amino acid that gives tea its calm. This is what keeps the focus calm instead of wired, and helps keep your attention into the afternoon.” The Benefits tab carries the second of those sentences.
5.1.2 Evidence. Keenan EK, Finnie MDA, Jones PS, Rogers PJ, Priestley CM (2011), How much theanine in a cup of tea? Effects of tea type and method of preparation, Food Chemistry 125(2):588–594; DOI 10.1016/j.foodchem.2010.08.071, quantifies a standard 200 ml cup of black tea at 24.2 ± 5.7 mg of L-theanine and a cup of green tea at 7.9 ± 3.8 mg. Nobre AC, Rao A, Owen GN (2008), L-theanine, a natural constituent in tea, and its effect on mental state, Asia Pacific Journal of Clinical Nutrition 17(Suppl 1):167–168; PMID 18296328, a two-page conference supplement by authors at a tea manufacturer's research institute, reports a greater increase in alpha-band electroencephalographic activity across time after a single 50 mg dose than after placebo (sixteen against nineteen participants), interpreted as relaxation without drowsiness; the paper notes that the alpha effect had previously been established only at doses above the roughly 20 mg in a cup of black tea, and it measured no cognitive or attention outcome. Foxe JJ, Morie KP, Laud PJ, Rowson MJ, de Bruin EA, Kelly SP (2012), Assessing the effects of caffeine and theanine on the maintenance of vigilance during a sustained attention task, Neuropharmacology 62(7):2320–2327; DOI 10.1016/j.neuropharm.2012.01.020; PMID 22326943 — twenty-seven participants performing a sustained-attention task over a two-hour session on each of four days, with 50 mg caffeine, 100 mg theanine, the combination or placebo — reports that error rates rose across the two hours on placebo and were significantly reduced after both caffeine and theanine, that the combination conferred no additional benefit, and that theanine alone did not affect alpha-band activity at all.
5.1.3 Reasoning. Anchoring an unfamiliar amino acid to tea is the fastest way to make it legible to a reader, and the “calm instead of wired” framing is the ingredient's real distinction from a stimulant. The vigilance evidence is the right shape for the second sentence: what the task measured was the flattening of a rise in errors as time on task grew.
5.1.4 Limitations. The dose is not a tea dose. A 200 ml cup of black tea delivers about 24 mg and a cup of green tea about 8 mg; the pouch delivers 200 mg, roughly eight cups of black tea, and the paper behind the calm framing states that the effect it measured had only been shown above the amount a cup contains. “Into the afternoon” rests on a single two-hour laboratory task in twenty-seven people on a single dose; two hours in a laboratory is not an afternoon of work, and nothing has tested a second half of a working day. The two halves of the sentence also rest on studies whose mechanisms disagree: the calm framing points at an alpha-wave finding, and the sustained-attention result comes from a study in which theanine alone produced no alpha change whatsoever. The European Food Safety Authority's 2011 opinion on L-theanine and cognitive function, stress and sleep (EFSA Journal 2011;9(6):2238; DOI 10.2903/j.efsa.2011.2238) concluded that no cause-and-effect relationship had been established for these effects; its title, journal and identifier are confirmed, but the full text would not return to us from the publisher's host or from the authority's own, so it is cited here by record rather than by passage.
5.2.1 Statement. The Benefits tab reads: “Many people enjoy taking Weal Focus alongside their morning coffee to maintain a focused energy throughout the day.” The directions read: “Many enjoy taking with morning coffee as the L-theanine means calm focus, not jitters.” The frequently-asked questions read: “The L-theanine is the ingredient most often paired with caffeine, because it promotes calm, steady focus without the jitters.”
5.2.2 Evidence. Owen GN, Parnell H, De Bruin EA, Rycroft JA (2008), The combined effects of L-theanine and caffeine on cognitive performance and mood, Nutritional Neuroscience 11(4):193–198; DOI 10.1179/147683008X301513; PMID 18681988 — twenty-seven volunteers, crossover, 50 mg caffeine with and without 100 mg L-theanine — reports that the combination improved both speed and accuracy on attention switching at sixty minutes and reduced susceptibility to distracting information. Giesbrecht T, Rycroft JA, Rowson MJ, De Bruin EA (2010), The combination of L-theanine and caffeine improves cognitive performance and increases subjective alertness, Nutritional Neuroscience 13(6):283–290; DOI 10.1179/147683010X12611460764840; PMID 21040626 — forty-four young adults, 97 mg L-theanine with 40 mg caffeine — reports significantly improved accuracy during task switching and self-reported alertness (both p < 0.01) and reduced tiredness (p < 0.05). Haskell CF, Kennedy DO, Milne AL, Wesnes KA, Scholey AB (2008), The effects of L-theanine, caffeine and their combination on cognition and mood, Biological Psychology 77(2):113–122; DOI 10.1016/j.biopsycho.2007.09.008; PMID 18006208, reports that the combination improved rapid visual information processing accuracy, mental fatigue ratings and reaction times, while theanine alone increased headache ratings and decreased correct serial seven subtractions. Payne ER, Aceves-Martins M, Dubost J, Greyling A, de Roos B (2025), Effects of Tea (Camellia sinensis) or its Bioactive Compounds l-Theanine or l-Theanine plus Caffeine on Cognition, Sleep, and Mood in Healthy Participants: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Nutrition Reviews 83(10):1873–1891; DOI 10.1093/nutrit/nuaf054; PMID 40314930; PMCID PMC12422004, pools attention-switching accuracy at hour two in favour of the combination (standardised mean difference 0.33; 95% confidence interval 0.13–0.54). Rogers PJ, Smith JE, Heatherley SV, Pleydell-Pearce CW (2008), Time for tea: mood, blood pressure and cognitive performance effects of caffeine and theanine administered alone and together, Psychopharmacology 195(4):569–577; DOI 10.1007/s00213-007-0938-1; PMID 17891480 — forty-eight healthy adults given 250 mg caffeine, 200 mg theanine, both or neither — is the only trial that measured jitteriness with both compounds, and reports that theanine antagonised caffeine's effect on blood pressure but “did not significantly affect jitteriness, alertness or other aspects of mood”, and that theanine slowed overall reaction time on a visual probe task.
5.2.3 Reasoning. The pairing has the best replication record in the theanine literature and is treated in meta-analysis as an intervention in its own right, so describing it as the ingredient most often paired with caffeine is accurate. The wording answers the question a coffee drinker asks before buying, and it does so without asking anyone to give up coffee.
5.2.4 Limitations. “Without the jitters” is the one caffeine-interaction outcome that has been measured head-on, at exactly our 200 mg, and it did not move; what theanine blunted in that trial was the rise in blood pressure, not the feeling. The replicated benefit is on attention-switching accuracy and self-reported alertness, which is what the trials support and what the causal clause does not say. Every positive combination trial gave between 40 and 150 mg of caffeine in the same capsule at the same moment; this product contains no caffeine, so the pairing the wording invites is one the purchaser assembles, at an amount and a timing nobody has tested. Theanine alone increased headache ratings and worsened one arithmetic measure in one of these trials. The three strongest combination trials and the meta-analysis were run or funded by tea companies, disclosed in each paper. The wording the alpha-wave evidence at clause 5.1.2 actually supports is “without drowsiness”, not “without the jitters”; the two are not equally evidenced, and this clause records which is which.
5.3.1 Statement. This clause governs the L-theanine element of the duration answer quoted at clause 8.2.1: “lion's mane and the four-week L-theanine work were measured over weeks and months of daily use”.
5.3.2 Evidence. Hidese S, Ogawa S, Ota M, Ishida I, Yasukawa Z, Ozeki M, Kunugi H (2019), Effects of L-Theanine Administration on Stress-Related Symptoms and Cognitive Functions in Healthy Adults: A Randomized Controlled Trial, Nutrients 11(10):2362; DOI 10.3390/nu11102362; PMID 31623400; PMCID PMC6836118. A randomised, placebo-controlled, double-blind crossover in thirty healthy adults — nine men and twenty-one women, mean age 48.3 (standard deviation 11.9), range 20 to 69 — taking 200 mg a day before sleep, the amount in this product, for four weeks per arm with a two-week washout. Against placebo, three Pittsburgh Sleep Quality Index subscales improved: sleep latency (p = 0.0499), sleep disturbance (p = 0.046) and use of sleep medication (p = 0.047). The paper states that “when score changes were compared between the L-theanine and placebo administrations, no significant difference was found for any cognitive function”; the cognitive results that are often quoted are within-arm before-and-after changes, and the one cognitive result that beat placebo came from a post-hoc split retaining the fifteen lowest baseline scorers, with no adjustment for multiple comparisons. Two instruments improved significantly after placebo. Two co-authors are employees of the company that supplied both the L-theanine and the placebo tablets, which funded the trial. Gerolymos C, Saddier E, Boyer L, Fond G (2026), Cognitive and affective effects of L-Theanine: a systematic review and meta-analysis of 31 randomized trials, Molecular Psychiatry, online ahead of print; DOI 10.1038/s41380-026-03727-9; PMID 42410082, finds the robust effect to be acute — a single 200 mg dose taken thirty to sixty minutes before testing improved choice reaction time (standardised mean difference 0.51; 95% confidence interval 0.25–0.77) — with acute stress reduction modest and “largely influenced by studies with a high risk of bias”, and describes the benefit as short-term; its full text is subscription-gated and was not read, so nothing here rests on anything beyond its abstract.
5.3.3 Reasoning. The duration answer is pinned to trial designs rather than to a promise, and four weeks is a real, checkable design fact at our exact dose.
5.3.4 Limitations. The trial is one trial, not a body of work, and the population is not adults over fifty: mean age 48.3, range 20 to 69. What survived four weeks against placebo was three sleep subscales, not a cognitive result; the trial states plainly that no cognitive measure differed from placebo in the full sample. “Months” has no L-theanine trial behind it: the longest dosing period among the thirty-one randomised trials in the 2026 meta-analysis appears to be eight weeks, at twice our dose, in a psychiatric population rather than in healthy adults — and that ranking could not be confirmed from the abstract. The strongest evidence for this ingredient concerns the dose taken that morning, not the month of taking it.
6. Zinc
6.1.1 Statement. The Benefits tab reads: “Zinc contributes to normal cognitive function, and your body cannot store it.” The ingredient card reads: “An essential mineral your body cannot store, so it has to arrive every day.”
6.1.2 Evidence. Commission Regulation (EU) No 432/2012 of 16 May 2012 establishing a list of permitted health claims made on foods, Annex; CELEX 32012R0432, carries the exact string “Zinc contributes to normal cognitive function” (claim identifier 296), usable only on a food that is at least a source of zinc; the identical wording is authorised for iodine (273) and iron (253). The underlying appraisal is the EFSA Panel on Dietetic Products, Nutrition and Allergies (2009), EFSA Journal 7(9):1229; DOI 10.2903/j.efsa.2009.1229, which concludes that “a cause and effect relationship has been established between the dietary intake of zinc and normal cognitive function”, and states immediately afterwards that “the evidence provided does not establish that inadequate intake of zinc leading to impaired cognitive function occurs in the general EU population”. The one adult supplementation trial the Panel reviewed — Maylor and colleagues, 2006, 387 healthy adults aged 55 to 87, zinc at 0, 15 or 30 mg a day for six months — found, of eight dependent variables, a benefit at three months only on one measure of spatial working memory and a detrimental effect of 15 mg a day on one measure of attention. On storage: King JC, Shames DM, Woodhouse LR (2000), Zinc homeostasis in humans, Journal of Nutrition 130(5S Suppl):1360S–1366S; PMID 10801944; DOI 10.1093/jn/130.5.1360S, reports that “adjustments in zinc absorption and endogenous intestinal excretion are the primary means of maintaining zinc homeostasis”, with secondary adjustments under prolonged marginal intake including “possibly, an avid retention of zinc released from selected tissues, such as bone, in other tissues to maintain function”. Institute of Medicine (2001), Dietary Reference Intakes, Chapter 12, Zinc; Bookshelf NBK222317, states that “over 85 percent of the total body zinc is found in skeletal muscle and bone”, that the combined size of the readily exchangeable zinc pools decreases with dietary restriction, and sets the Estimated Average Requirement at 9.4 mg a day for men and 6.8 mg for women, the Recommended Dietary Allowance at 11 mg and 8 mg, and the Tolerable Upper Intake Level at 40 mg. The Office of Dietary Supplements zinc fact sheet formerly stated that “a daily intake of zinc is required to maintain a steady state because the body has no specialized zinc storage system”; the current edition has removed that sentence and states instead that the body holds approximately 1.5 g of zinc in women and 2.5 g in men, most of it in skeletal muscle and bone. The live page would not return to us; both editions were read in Internet Archive captures.
6.1.3 Reasoning. The cognitive sentence is the exact authorised form of words in the jurisdiction that authorises it, and 15 mg clears the “source of zinc” condition many times over. The storage clause is the plainest way to say why a mineral has to be taken habitually rather than occasionally.
6.1.4 Limitations. The authorisation is European and has no force in the United States, where the same sentence is a structure/function statement carrying the disclaimer printed at the close of this page; and because the identical wording is authorised for iron and iodine, it is a generic nutrient formula rather than evidence that zinc does something particular for focus. In the authorising vocabulary, “normal function” means maintaining function against a background of adequate intake, and the Panel expressly did not establish that inadequate zinc intake causes impaired cognitive function in the general population; the one adult supplementation trial it reviewed was essentially null and contained a detrimental attention signal at the amount this product uses. “Cannot store it” is false as a statement of fact: the body holds one and a half to two and a half grams, most of it in muscle and bone, and bone zinc can be released and redistributed under prolonged marginal intake. What is true is that there is no specialized, rapidly mobilizable zinc depot of the kind iron has, so status is held by adjusting absorption and gut excretion rather than by drawing on a reserve — and the federal sentence that said so has been deleted from the live fact sheet, so a reader checking the obvious source today will not find it. Homeostatic adjustment also buffers day-to-day variation, so what matters is habitual intake over weeks rather than an unbroken daily record.
6.2.1 Statement. The Benefits tab and the zinc ingredient card read: “roughly 1 in 4 American adults falls short of the zinc they need from food, rising to almost 1 in 2 for those over 60.”
6.2.2 Evidence. United States Department of Agriculture, Agricultural Research Service (2023), Usual Nutrient Intake from Food and Beverages, by Gender and Age, What We Eat in America, NHANES 2017–March 2020 Prepandemic, Table A38, Zinc — nationally representative usual intakes from food and beverages only, 3,840 men and 3,926 women aged nineteen and over, assessed against the Estimated Average Requirement by the cut-point method — reports the proportion below the requirement as 22 per cent of men aged nineteen and over (standard error 2.2) and 20 per cent of women (1.9); by age, men 51 to 70 at 22 per cent and men 71 and over at 29 per cent, women 51 to 70 at 19 per cent and women 71 and over at 26 per cent. There is no bracket for people over sixty; the brackets that straddle sixty run from 19 to 29 per cent. Reider CA, Chung R-Y, Devarshi PP, Grant RW, Hazels Mitmesser S (2020), Inadequacy of Immune Health Nutrients: Intakes in US Adults, the 2005–2016 NHANES, Nutrients 12(6):1735; PMID 32531972; DOI 10.3390/nu12061735; PMCID PMC7352522 — 26,282 adults; all five authors employed by a supplement manufacturer — reports 15 per cent of adults below the requirement from food alone and 11 per cent once supplements are counted; this is the figure the current federal fact sheet cites. Ervin RB, Kennedy-Stephenson J (2002), Mineral intakes of elderly adult supplement and non-supplement users in the third national health and nutrition examination survey, Journal of Nutrition 132(11):3422–3427; PMID 12421862; DOI 10.1093/jn/132.11.3422, on survey fieldwork conducted between 1988 and 1994, reports inadequate dietary zinc intakes in 35 to 41 per cent of elderly males and 36 to 45 per cent of elderly females; a supplement-inclusive figure of 20 to 25 per cent for the same population appeared in an earlier edition of the federal fact sheet and has since been removed from it. Freedman and colleagues (2024), American Journal of Clinical Nutrition 119:1309–1320; PMID 38373695, reports significant increases in the proportion below the requirement for zinc from food in both sexes across the 2003 to 2018 survey cycles.
6.2.3 Reasoning. Both fractions were chosen by us as round figures for a sentence a reader skims. “Roughly 1 in 4” is defensible as a round-up of a current food-only figure of about 21 per cent in a series that is rising.
6.2.4 Limitations. Both figures are higher than their sources, and the second materially so. Against the most recent national survey, “roughly 1 in 4” is about four points high; against the figure the federal fact sheet publishes for adults, it is ten points high. “Almost 1 in 2 for those over 60” has no current support at all: the brackets that straddle sixty run from 19 to 29 per cent, the highest adult figure anywhere in the table is 29 per cent for men aged 71 and over, and the product page's fraction is therefore roughly double. The only published number near 45 per cent is the top of one sex's range in a survey whose fieldwork ended in 1994, before the supplement correction that an earlier edition of the federal fact sheet reported for the same survey and that has since been removed from that page. There is no published bracket for adults over sixty, so the wording implies a cut the data do not contain. Finally, being below the Estimated Average Requirement is not the same as falling short of what one needs: the requirement is a median, so an intake below it carries a greater-than-even probability of inadequacy for an individual, not a certainty.
6.3.1 Statement. The third tile of the numbers block reads: “1 in 2 — American adults over 60 get less zinc from food than the estimated average requirement.”
6.3.2 Evidence. As at clause 6.2.2. The preceding survey cycle, What We Eat in America, NHANES 2013–2016, Table A38, puts men aged 51 to 70 at 18 per cent, men 71 and over at 27 per cent, women 51 to 70 at 18 per cent and women 71 and over at 27 per cent — two consecutive national cycles placing older-adult zinc inadequacy from food in an 18 to 29 per cent band.
6.3.3 Reasoning. The tile is the fraction at clause 6.2.1 with its hedge removed, chosen by us for a block that carries figures in large type.
6.3.4 Limitations. Nothing published supports one in two. The best current estimate for the oldest adults, from food alone, is 29 per cent of men and 26 per cent of women aged 71 and over; for adults 51 and over it is 24 per cent and 21 per cent. The tile is therefore between twenty-one and twenty-four points above the published figures for the oldest adults and is roughly double the figure for the group it names, and it states without qualification a number the paragraph version at least hedges. There is also no published bracket for adults over sixty. The only value approaching one in two anywhere in the source table — 49 per cent — belongs to females aged 14 to 18, an adolescent bracket and not an adult one. The figure that is both current and true, and which makes the same point about older adults, is that about one in four Americans aged 71 and over gets less zinc from food than the estimated average requirement.
7. Vitamin B12
7.1.1 Statement. The Benefits tab and the ingredient card both read: “Vitamin B12 maintains the myelin around your nerves, supports normal nervous system function, and helps turn food into energy.”
7.1.2 Evidence. Stabler SP (2013), Clinical Practice: Vitamin B12 Deficiency, New England Journal of Medicine 368(2):149–160; DOI 10.1056/NEJMcp1113996; PMID 23301732: “Vitamin B12 is necessary for the development and initial myelination of the central nervous system as well as for the maintenance of its normal function,” with demyelination of the spinal cord, cranial and peripheral nerves and cerebral white matter described as consequences of deficiency, and vitamin B12 identified as “a cofactor for only two enzymes: methionine synthase and l-methylmalonyl–coenzyme A mutase”. The Office of Dietary Supplements fact sheet on vitamin B12 states that “vitamin B12 is required for the development, myelination, and function of the central nervous system; healthy red blood cell formation; and DNA synthesis”, and describes L-methylmalonyl-CoA mutase converting L-methylmalonyl-CoA to succinyl-CoA; the live page would not return to us and was read in an Internet Archive capture of 13 September 2026. Commission Regulation (EU) No 432/2012, Annex; CELEX 32012R0432, authorises “Vitamin B12 contributes to normal functioning of the nervous system” (claim identifiers 95, 97, 98, 100, 102 and 109) and “Vitamin B12 contributes to normal energy-yielding metabolism” (99 and 190), resting on EFSA Journal opinions 2009;7(9):1223; DOI 10.2903/j.efsa.2009.1223 and 2010;8(10):1756; DOI 10.2903/j.efsa.2010.1756. The word “myelin” appears nowhere in that Regulation.
7.1.3 Reasoning. Myelin is the most concrete and physical thing this vitamin does, and it is what the clinical literature and the federal summary both say B12 builds and maintains. The energy clause is the plain-English form of a claim authorised in the European Union, and it describes a step in metabolism rather than a subjective state.
7.1.4 Limitations. Every source here describes what happens when B12 is absent, not what happens when a person who already has enough takes more; no trial shows that supplementing a replete adult maintains myelin better. The authorisations cited are European and have no force in the United States, where these are structure/function statements; and “myelin” is more specific than either the authorised wording or anything reviewed in the United States, with the nearest supporting literature reaching it through demyelinating disease. “Helps turn food into energy” describes biochemistry, not pep: the same federal fact sheet records that evidence from randomised trials does not show that B12 supplementation, alone or with other B vitamins, improves cognitive function in older adults over one to two years, even where it lowers homocysteine.
7.2.1 Statement. Two wordings are live. The Benefits tab reads: “Absorption falls with age, which is why we use methylcobalamin, a ready-to-be-absorbed form of B12 that your body's natural enzymes can readily use.” The ingredient card carries the same sentence with a dash in place of the comma: “Absorption falls with age, which is why we use methylcobalamin — a ready-to-be-absorbed form of B12 that your body's natural enzymes can readily use.”
7.2.2 Evidence. Institute of Medicine (1998), Dietary Reference Intakes, Chapter 9, Vitamin B12; DOI 10.17226/6015, sets the Recommended Dietary Allowance at 2.4 µg a day for adults and states that “because 10 to 30 percent of older people may be unable to absorb naturally occurring vitamin B12, it is advisable for those older than 50 years to meet their RDA mainly by consuming foods fortified with vitamin B12 or a vitamin B12-containing supplement”, adding that the bioavailability of crystalline B12 is not altered in people with atrophic gastritis. Stabler 2013, cited at clause 7.1.2, reports that milder atrophic gastritis with an inability to release protein-bound B12 from food affects up to 20 per cent of older adults and that healthy older adults should consider supplemental crystalline vitamin B12. The Office of Dietary Supplements fact sheet states that B12 added to fortified foods and supplements “is already in free form and therefore does not require the separation step”, and that methylcobalamin and 5-deoxyadenosylcobalamin are the metabolically active forms. Obeid R, Fedosov SN, Nexo E (2015), Cobalamin coenzyme forms are not likely to be superior to cyano- and hydroxyl-cobalamin in prevention or treatment of cobalamin deficiency, Molecular Nutrition & Food Research 59(7):1364–1372; DOI 10.1002/mnfr.201500019; PMID 25820384; PMCID PMC4692085, concludes that “we do not have sufficient evidence to suggest that the benefits of using MeCbl or AdoCbl override that of using CNCbl or HOCbl in terms of bioavailability, biochemical effects, or clinical efficacy”, and records that dealkylation inside the cell is obligatory before the coenzymes are rebuilt. Paul C, Brady DM (2017), Comparative Bioavailability and Utilization of Particular Forms of B12 Supplements With Potential to Mitigate B12-related Genetic Polymorphisms, Integrative Medicine (Encinitas) 16(1):42–49; PMID 28223907; PMCID PMC5312744, which argues for the natural cobalamin forms and whose co-author is an officer of a supplement manufacturer, nonetheless states that “absorption in the blood of the 2 B12 forms was similar”, a line from the single animal study on which its retention argument also rests, and that “for the majority of the population, all B12 forms may likely have similar bioavailabilities and physiological effects”.
7.2.3 Reasoning. The first half is the single best-evidenced argument for taking supplemental B12 at all, and it is the argument the Institute of Medicine itself makes. Methylcobalamin is one of the two coenzyme forms the body uses directly, and it is the form we chose.
7.2.4 Limitations. The causal link between the two halves outruns the evidence. What the age argument selects for is free, crystalline B12 of any kind — which is what fortified foods and supplements contain, cyanocobalamin included — not methylcobalamin specifically. Methylcobalamin is a coenzyme form, not a more-absorbable one; the best evidence puts the absorption of the two forms at parity, and the review written to defend the natural forms says so. “Ready-to-be-absorbed” also conflates absorption with metabolic readiness, and the methyl group is in any case removed inside the cell before the coenzymes are rebuilt. Our choice of form is a preference among forms the body uses directly; it is not what answers age-related malabsorption.
7.3.1 Statement. The fourth tile of the numbers block reads: “1 in 8 — American adults have less vitamin B12 than the recommended daily amount.”
7.3.2 Evidence. The figure is 12.5 per cent, from Zhou Y, Wang A, Yeung LF, Qi YP, Pfeiffer CM, Crider KS (2023), Folate and vitamin B12 usual intake and biomarker status by intake source in United States adults aged ≥19 y: NHANES 2007–2018, American Journal of Clinical Nutrition 118(1):241–254; DOI 10.1016/j.ajcnut.2023.05.016; PMID 37172826; PMCID PMC10926004, and repeated in the federal fact sheet: serum vitamin B12 insufficiency, defined as below 300 pg/mL (221 pmol/L), affects approximately 12.5 per cent of adults aged nineteen and over, and 12.3 per cent of those aged sixty and over, while deficiency below 200 pg/mL affects 3.6 per cent. That is a blood measurement, not an intake measurement, and it rests on a shorter window than the title of the paper states: serum vitamin B12 was available only for the 2011 to 2014 cycles, in 9,297 participants, while the intake analysis covers 31,128 adults aged nineteen and over across 2007 to 2018. On intake, the same paper reports that the twenty-fifth percentile of vitamin B12 intake was above the Estimated Average Requirement in every demographic subgroup examined; and the United States Department of Agriculture, Agricultural Research Service (2023), Usual Nutrient Intake from Food and Beverages, by Gender and Age, What We Eat in America, NHANES 2017–March 2020 Prepandemic, Table A26, Vitamin B12, reports that the proportion of adults aged nineteen and over below the Estimated Average Requirement of 2 µg a day from food and beverages is 5 per cent of men and 11 per cent of women, with mean usual intakes of 5.73 µg and 3.77 µg a day against a Recommended Dietary Allowance of 2.4 µg.
7.3.3 Reasoning. The fraction was chosen by us as a round figure from a real and well-sourced federal number, for a block whose choline and zinc tiles carry intake figures.
7.3.4 Limitations. The number is true of something the label does not say. 12.5 per cent is the share of adults whose blood level falls below an insufficiency screening threshold, not the share whose intake falls below a recommended amount. The published intake figures point the other way: about 5 per cent of men and 11 per cent of women fall below the Estimated Average Requirement from food and beverages — roughly one in twelve adults combined, a combination that is ours rather than the survey's — and the twenty-fifth percentile of intake exceeds the requirement in every subgroup examined. There is a second slippage inside the label: “the recommended daily amount” is the Recommended Dietary Allowance or the Daily Value, both 2.4 µg, while every published shortfall figure is measured against the Estimated Average Requirement of 2 µg, and no agency publishes a below-allowance prevalence, so the precise quantity the label describes does not exist in any source. The blood figure is also highly threshold-dependent — about 3 per cent at one cut-off and about 26 per cent at another in an earlier survey window — and most people in the intermediate band have no symptoms. The supported version of the same number is that about one in eight American adults has a vitamin B12 level below the insufficiency threshold.
8. The six-month timeline
8.1.1 Statement. The Month 2 panel of “What the first six months look like” reads: “This is the window where published trials begin measuring change.”
8.1.2 Evidence. The first post-baseline assessment in the twelve-week lion's mane trial (Saitsu 2019, clause 4.1.2) was at six weeks; the first separation from placebo in the sixteen-week trial (Mori 2009, clause 4.1.2) was at week 8. For alpha-GPC, the largest trial — De Jesus Moreno Moreno M (2003), Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial, Clinical Therapeutics 25(1):178–193; PMID 12637119; DOI 10.1016/S0149-2918(03)90023-3 — gave 1,200 mg a day to 261 patients with mild-to-moderate Alzheimer-type dementia for 180 days, and took its first post-baseline measurement at day 90. The four-week L-theanine trial (Hidese 2019, clause 5.3.2) measured at its four-week endpoint. The acute alpha-GPC trial (Kerksick 2024, clause 2.1.2) measured at sixty minutes.
8.1.3 Reasoning. The sentence moves the Month 2 panel off the purchaser's body and onto the published record, where it is checkable: it says that trials measured, not that anyone will feel something.
8.1.4 Limitations. Month 2 is where only the lion's mane literature lands. The alpha-GPC trial with a fixed measurement schedule did not measure until day 90, a month later than the panel implies; the L-theanine endpoint fell at week 4, a month earlier; and the acute alpha-GPC measurement was within the hour. The honest span therefore runs from a single dose to day 90 depending which ingredient is meant. None of these trials used our formula or our purchasers, and only the L-theanine trial used one of our amounts: the lion's mane trials used seven to eight times our amount, one in a population with diagnosed impairment, and the 180-day alpha-GPC trial used four times our amount in patients with dementia. Because the sentence sits inside a timeline, a reader may take “trials begin measuring change here” to mean that something will be noticed here, which no trial licenses.
8.2.1 Statement. The frequently-asked questions read: “Weeks to months, not days… Alpha-GPC has been measured after a single dose; lion's mane and the four-week L-theanine work were measured over weeks and months of daily use.”
8.2.2 Evidence. As a statement about trial designs this is accurate. The shortest daily-use trials of these ingredients ran twenty-eight days (Docherty 2023) and four weeks (Hidese 2019); the others ran twelve weeks (Saitsu 2019), sixteen weeks (Mori 2009) and 180 days (De Jesus Moreno 2003). Alpha-GPC has been measured acutely at sixty minutes after a single dose (Kerksick 2024). The sixteen-week lion's mane trial is the strongest support for “not days”: its scores fell significantly within four weeks of intake stopping.
8.2.3 Reasoning. The answer sets a purchaser's expectation low and ties it to trial durations rather than to a promise, and it is the one place on the product page where the single-dose nature of the alpha-GPC evidence is disclosed to a reader.
8.2.4 Limitations. There is one four-week L-theanine trial, not a body of work, and its population is not adults over fifty: mean age 48.3, range 20 to 69 — clause 5.3.4 sets out what it did and did not find. “Months” is carried by the lion's mane trials and by the 180-day alpha-GPC trial in Alzheimer-type dementia; no L-theanine trial supports it. The twenty-eight-day lion's mane trial found nothing significant on cognition. And the answer is in tension with the rest of the page: it tells a reader to expect weeks to months while the site's one efficacy figure comes from a single-dose measurement. That tension is not a citation error but it is a real one, and it is recorded here rather than resolved in the copy.
8.3.1 Statement. The Month 1 panel reads: “Many people take it alongside their morning coffee. The L-theanine keeps their focus calm rather than wired. One pouch is exactly 30 days.” The second line of the same panel reads: “In the first few weeks, Alpha-GPC starts supporting healthy concentration and steady energy.”
8.3.2 Evidence. The coffee pairing is governed by clause 5.2 and rests on the combination trials cited there. The pouch count is governed by clause 9.4 and rests on the label specification. For the second line, no trial of the finished product exists; the ingredient evidence is at clauses 2.1 to 2.3 for alpha-GPC's measured attention result, which was acute, and at clauses 4.1 and 5.3 for the ingredients measured over weeks.
8.3.3 Reasoning. “Starts supporting” is a structure/function form of words describing a role, not a promised effect, and it is deliberately not a claim that anything is felt in the first few weeks.
8.3.4 Limitations. No published research bears on what alpha-GPC does over the first few weeks of daily use at 300 mg in a purchaser of this formula: the trial that measured an attention effect measured it within hours of one dose, and the trials that ran for weeks used other ingredients, other doses and other populations. “Steady energy” is not an endpoint any trial cited on this page measured.
8.4.1 Statement. Four lines of the timeline describe an experience on a schedule: “Many customers feel elevated levels of attention” (Month 1); “Signs of improved mental clarity start emerging” (Month 2); “this is the stretch where days can feel less sluggish and energy steadier throughout the afternoon” (Month 3); and “This is when the effects begin to truly show”, with “Ongoing support for healthy focus and clarity”, at six months and beyond.
8.4.2 Evidence. None of these lines rests on a trial. Weal Focus, the finished product, has never been the subject of a trial, so no measurement exists of what a person taking it experiences at one month, two, three or six. The ingredient trials that ran long enough to speak to a schedule are set out at clauses 4.1.2, 5.3.2 and 8.1.2; each used a single ingredient — at doses between four and eight times ours, save the L-theanine trial, which used the 200 mg in this product — in populations named in those clauses.
8.4.3 Reasoning. The timeline exists to set the expectation that this is a habit rather than a dose, and these four lines describe the pattern of use we expect a purchaser to settle into over six months.
8.4.4 Limitations. They are not findings and no clause on this page is evidence for them. Each is written in the conditional or the general — “can feel”, “start emerging”, “begin to show” — and none should be read as a measured outcome, an average result, or a schedule any trial has established. The Month 1 line refers to the experience of people taking the product; no trial has measured that experience, and nothing on this page supports it as a research finding. The six-month line asserts a point in time at which effects show, and no published research bears on the finished formulation at any duration.
9. Statements about the product itself
9.1.1 Statement. The Supplement Facts panel declares a serving of two capsules and the following amounts.
| Ingredient | Amount per serving | % Daily Value |
|---|---|---|
| Alpha-GPC (L-alpha-glycerylphosphorylcholine) | 300 mg | Daily Value not established |
| Lion's mane extract 8:1 | 400 mg | Daily Value not established |
| L-theanine | 200 mg | Daily Value not established |
| Zinc (as zinc picolinate) | 15 mg | 136 |
| Vitamin B12 (as methylcobalamin) | 500 mcg | 20,833 |
9.1.2 Evidence. The amounts are those in our label specification and are the amounts stated to the manufacturer, Guangzhou Yinglian Health Industry Co., Ltd. The reference values behind the two percentages are the Daily Values for zinc and vitamin B12. The relevant limits are set by the Institute of Medicine (2001), Chapter 12, Zinc; Bookshelf NBK222317, which sets a Tolerable Upper Intake Level of 40 mg a day for zinc, and the Institute of Medicine (1998), Chapter 9, Vitamin B12; DOI 10.17226/6015, which sets no Upper Intake Level for vitamin B12.
9.1.3 Reasoning. The panel is transcribed here exactly as it is declared, including the extract ratio, so that a reader comparing this page with the pouch finds the same words in the same order. The extract ratio is printed because it is the only bridge between our 400 mg and the gram quantities used in the published lion's mane trials, and clause 4.1.4 depends on it.
9.1.4 Limitations. Two percentages of Daily Value are large: zinc at 136 per cent and vitamin B12 at 20,833 per cent. The zinc amount sits well below the Tolerable Upper Intake Level of 40 mg a day, and vitamin B12 has no Upper Intake Level. A percentage of a Daily Value is a ratio to a reference amount rather than a measure of effect, and every trial cited on this page tested a single ingredient rather than this formula.
9.2.1 Statement. Three transparency wordings are governed together by this clause. The buy box reads: “No proprietary blends, no hidden ingredients.” The Benefits tab closes: “Every amount is printed on the pouch, and no ingredients are hidden.” The five-ingredients section opens: “Nothing is hidden in our blend, and every figure is traceable on the citations page.”
9.2.2 Evidence. The Supplement Facts panel transcribed at clause 9.1.1 declares each ingredient with its own amount and its chemical form, and no ingredient is declared inside a combined blend total. Every figure printed on the product page is the subject of a numbered clause on this page, and each clause names its sources with permanent identifiers.
9.2.3 Reasoning. The absence of a proprietary blend is a verifiable property of the panel rather than a characterisation of it, and the reference to traceability is the reason this page exists.
9.2.4 Limitations. “Nothing is hidden” is a statement about the declaration of ingredients and amounts: each is declared with its own amount and its own chemical form, and none sits inside a combined blend total. Traceability is discharged to the extent of what this page records, and clause 11.1 indexes the clauses where a wording reaches to the edge of its source.
9.3.1 Statement. The five-ingredients section reads: “We always use the highest quality form of each ingredient.” The same formulation appears for individual ingredients at clauses 2.4.1 and 4.2.1.
9.3.2 Evidence. The decisions the phrase describes are: alpha-GPC rather than choline bitartrate or chloride, a choline compound on a glycerophosphate backbone; lion's mane fruiting body to a beta-glucan specification rather than mycelium grown on grain, a distinction supported by the analytical work at clause 4.2.2; methylcobalamin, one of the two coenzyme forms of vitamin B12, rather than cyanocobalamin; zinc picolinate; and L-theanine at 200 mg. Each is a choice of form and specification. None rests on a measured ranking of that form against the alternatives.
9.3.3 Reasoning. “Highest quality” is a purchasing standard: it says what we buy and what we decline to buy, at a cost several times that of the commodity alternatives.
9.3.4 Limitations. Read as a measured ranking it is not supported for any of the five. The only oral human head-to-head of choline forms found no difference in absorption and placed alpha-GPC numerically lowest over six hours (clause 2.5.4); the best evidence puts methylcobalamin and cyanocobalamin at parity for absorption, and the review arguing for the coenzyme forms says so (clause 7.2.4); no document in our possession substantiates a ranking of lion's mane raw materials on any outcome, and the longest chronic trial of the mushroom used the mycelium our specification excludes (clause 4.2.4). The word “always” makes the sentence a claim about all five ingredients at once, and no clause on this page is evidence for it as a ranking.
9.4.1 Statement. The directions read: “Two capsules daily.” The frequently-asked questions read: “Two capsules daily. One pouch is 60 capsules — a 30-day supply.” The Month 1 panel reads: “One pouch is exactly 30 days.” The directions close: “Keep the pouch sealed and stored somewhere cool and dry.” The pouch declares “60 CAPSULES / 30 SERVINGS / NET WT 1.28 OZ (36 g)”.
9.4.2 Evidence. Sixty capsules at a serving of two capsules a day is thirty servings; the arithmetic is exact and carries no rounding. 21 CFR 101.36(b)(1)(i) requires the serving size to be expressed “using a term that is appropriate for the form of the supplement, such as ‘tablets,’ ‘capsules,’ ‘packets,’ or ‘teaspoonfuls’” — capsules being one of the regulation's own examples of an appropriate term rather than a required one. 21 CFR 101.36(b)(1)(ii) requires servings per container to be placed under the serving size on the nutrition label, “except that this information need not be provided when it is stated in the net quantity of contents declaration”, which is where the pouch states it. The net quantity declaration itself is governed by 21 CFR 101.105. The declared net weight is computed rather than weighed: the manufacturer's fill specification is approximately 0.51 g per capsule, and an empty size 0 hypromellose shell weighs approximately 0.096 g, so sixty capsules give 36.36 g, printed as 36 g and 1.28 oz. The storage direction follows from the formula: alpha-GPC is hygroscopic, which is why the pouch is foil-lined and carries a desiccant.
9.4.3 Reasoning. The pack is sized to the serving so that a pouch and a month end together, and the figures on the page are the figures on the pack.
9.4.4 Limitations. “A 30-day supply” is a labelling convention derived from the stated serving; it is not a measurement of how long any individual's pouch lasts, and anyone taking the product on some days and not others will have it last longer. It says nothing about how long any effect lasts. The net weight is a computed declaration — fill specification plus empty shell weight, per capsule, multiplied by sixty — rather than a figure read off a scale, and if the fill specification or the shell changes the declaration has to be recomputed rather than carried over.
9.5.1 Statement. The laboratory badge reads: “Lab tested — 11 substances tested for quality · Shunjin Testing · September 2026 · lot 20260701.” Its dialog names Shenzhen Shunjin Testing Technology, report SHUN2609024025S, issued 8 September 2026, lot 20260701, and lists the results below. The numbers block carries the line “Third-party lab tested for safety.”
9.5.2 Evidence. Shenzhen Shunjin Testing Technology Co., Ltd, test report SHUN2609024025S, version 1.0, issued 8 September 2026. Product “Alpha-GPC CAPSULES”; applicant and manufacturer both Guangzhou Yinglian Health Industry Co., Ltd; lot 20260701; sample received 2 September 2026; testing period 2 to 8 September 2026. Sense tests recorded the sample as capsule form, odourless and white. The eleven substances are these.
| Substance | Method | Result |
|---|---|---|
| Lead | ICP-MS after microwave digestion | Not detected (limit 10 mg/kg) |
| Mercury | ICP-MS after microwave digestion | Not detected (limit 1 mg/kg) |
| Arsenic | ICP-MS after microwave digestion | Not detected (limit 2 mg/kg) |
| Antimony | ICP-MS after microwave digestion | Not detected (limit 3 mg/kg) |
| Cadmium | ICP-MS after microwave digestion | Not detected (limit 5 mg/kg) |
| Aerobic mesophilic bacteria | ISO 21149 | Not detected (limit 100 CFU/g) |
| Mould and yeast | ISO 16212 | Not detected (limit 100 CFU/g) |
| Pseudomonas aeruginosa | ISO 22717 | Absent per gram |
| Staphylococcus aureus | ISO 22718 | Absent per gram |
| Escherichia coli | ISO 21150 | Absent per gram |
| Candida albicans | ISO 18416 | Absent per gram |
The report's conclusion reads: “Based on the performed tests on submitted sample(s), the results comply with Customer request.”
9.5.3 Reasoning. The badge names the laboratory, the report number, the issue date and the lot so that the report can be identified and requested, rather than asserting that testing occurred. The count of eleven is the count of substances in the table above.
9.5.4 Limitations. The report covers a submitted sample of one lot, and it is a product test rather than a facility audit; the manufacturing standard is governed by clause 9.6. What it establishes is safety — five heavy metals not detected by inductively coupled plasma mass spectrometry, and six microbiological tests clean to published ISO methods — and that is the sense in which the site says “Third-party lab tested for safety”. Its composition heading records the three actives that carry the blend by weight, lion's mane extract at 45 per cent, alpha-GPC at 35 per cent and L-theanine at 20 per cent, in the proportions our specification sets; zinc and vitamin B12 are declared on the panel at 15 mg and 500 mcg.
9.6.1 Statement. The guarantee chips and the buy box read “Made in a cGMP facility.” The badge in which that phrase appears reads in full: “30-day returns · Free US shipping · Made in a cGMP facility.” The first two elements of that badge are governed by clause 9.7.
9.6.2 Evidence. 21 CFR Part 111, Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, final rule published at 72 FR 34752 on 25 June 2007 and effective 24 August 2007. Section 111.1(a) provides that “you are subject to this part if you manufacture, package, label, or hold a dietary supplement, including … (2) A dietary supplement imported or offered for import in any State or territory of the United States, the District of Columbia, or the Commonwealth of Puerto Rico,” so a foreign contract manufacturer producing for the United States market is inside the rule exactly as a domestic one is. Compliance dates ran by firm size and the rule has bound firms of every size since 25 June 2010. The Food and Drug Administration's small entity compliance guide of December 2010, which is non-binding by its own terms, restates that scope and describes no mechanism by which a facility is certified, audited or approved as compliant.
9.6.3 Reasoning. The phrase names a standard rather than a credential, because there is no credential to name: Part 111 compliance is a legal duty owed by every firm manufacturing a dietary supplement for this market, and formulations such as “FDA-registered facility” or “FDA-approved facility” describe an approval the agency does not give. The agency's own consumer page states that “under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed”.
9.6.4 Limitations. The statement names a standard rather than a credential. Part 111 binds every firm manufacturing a dietary supplement for this market, so the phrase describes the rule our manufacturer works under rather than something that distinguishes this product from another lawfully sold here. Our specification requires that compliance of the manufacturer, and the facility documentation evidencing it is held by the manufacturer rather than by us.
9.7.1 Statement. The following are statements of policy and of service. The badge reads “30-day returns · Free US shipping”. The announcement bar reads “Free shipping · 30-day returns”. The frequently-asked questions read: “Orders leave our US warehouse within 2–3 business days, with free shipping inside the US”; “Send it back within 30 days of delivery for a refund”; and “Tick Subscribe for a recurring discount. Delivery repeats on the timeline you choose: every 30 days for one pouch, 90 for three, 150 for five.”
9.7.2 Evidence. These are our own undertakings, given in our published terms of sale and delivery policy, and the subscription intervals are the intervals our store offers. The subscription cadence follows from the serving at clause 9.4: thirty days for one pouch, ninety for three, one hundred and fifty for five.
9.7.3 Reasoning. Each is stated as a term rather than as an expectation, so that a purchaser can hold us to it.
9.7.4 Limitations. They are undertakings, not claims about composition or effect, and no clause on this page is evidence for any of them; they are substantiated by performance rather than by citation. The third element of the badge in which two of them appear — “Made in a cGMP facility” — is a claim requiring evidence and is governed by clause 9.6, including that clause's limitations.
9.8.1 Statement. Three product-level statements about effect are governed by this clause. The buy box reads “Supports long-term mental clarity and sustained energy” and “Promotes steady attention for adults of every age.” The six-month panel reads “Ongoing support for healthy focus and clarity.”
9.8.2 Evidence. These are structure/function statements under 21 CFR 101.93(f). They rest on the roles of the individual ingredients set out in sections 2 to 7: choline as the substrate for acetylcholine (clause 3.3), lion's mane's authorised cognitive-function role (clause 4.1), L-theanine's measured effect on sustained-attention error rates within a session (clause 5.1), zinc's authorised cognitive-function role in the European Union (clause 6.1), and vitamin B12's authorised nervous-system and energy-metabolism roles in the European Union (clause 7.1).
9.8.3 Reasoning. Each describes a role rather than a result, names no disease, and promises no measurable change, which is the form the regulation permits and the only form the evidence at these amounts will carry.
9.8.4 Limitations. Weal Focus, the finished product, has never been the subject of a trial, so no evidence bears on the finished formulation over any duration — “long-term” and “ongoing” describe the pattern of intended use and the durations of the ingredient trials recorded at clauses 4.1.2, 5.3.2 and 8.1.2, not a measured persistence of any effect in a purchaser. “For adults of every age” is broader than any evidence cited on this page: the alpha-GPC attention result is from twenty men aged 20 to 55 (mean 31.3, standard deviation 11.0) in a single crossover; the positive chronic lion's mane trials are in adults over fifty, one group with diagnosed mild cognitive impairment; the acute lion's mane trials are in adults aged 18 to 45 and 18 to 35; the four-week L-theanine trial ranged from 20 to 69; and no cited trial covers the whole adult range for any ingredient, let alone for the formula. “Sustained energy” is not an endpoint measured in any trial cited here.
9.9.1 Statement. The frequently-asked questions read: “It is for adults 18 and over. Anyone pregnant or nursing, taking medication — particularly cholinergic or anticholinergic medication — or managing a medical condition should talk to their physician first.”
9.9.2 Evidence. Health Canada (2024), cited at clause 2.4.2, records human safety data for alpha-GPC at up to 1,200 mg a day for up to six months and none above that. Lee 2021, cited at clause 2.13.2, reports a higher ten-year risk of stroke in matched alpha-GPC users in a prescribed population aged fifty and over, with a dose-response relationship by prescription duration. The Institute of Medicine sets the Tolerable Upper Intake Level for zinc at 40 mg a day, against 15 mg here, and sets none for vitamin B12. Docherty 2023, cited at clause 4.1.2, reports no serious adverse events; Li and colleagues 2020, cited at clause 4.2.4, records four withdrawals for abdominal discomfort, nausea and skin rash on a mycelium preparation at a higher dose. The caution about cholinergic and anticholinergic medication follows from the mechanism described in section 2: the product supplies a precursor to a transmitter that such medicines are prescribed to raise or to block.
9.9.3 Reasoning. The caution is set at the boundary of the evidence rather than at the boundary of the risk we can demonstrate: the populations studied are adults, pregnancy and nursing have not been studied for this formula, and a person on medication acting on the same transmitter system has a reason to ask before adding a precursor to it.
9.9.4 Limitations. No trial of the finished product exists, so no safety finding bears on this formula as sold; the evidence is ingredient-by-ingredient, at doses mostly above ours and in populations mostly older than the general adult population. The stroke association above is observational, in a population prescribed the compound at pharmaceutical doses, and is confounded by the reason for prescription; it cannot establish cause. It is nonetheless the most serious signal attached to any ingredient in this formula and it is recorded here rather than omitted.
10. Figures cited in the Journal
10.1.1 Statement. A piece in the Journal states that habitual choline intake in the United States remains below the Adequate Intake, citing Trujillo-Gonzalez and colleagues.
10.1.2 Evidence. Trujillo-Gonzalez I and colleagues (2026), American Journal of Clinical Nutrition 123(4):101236; DOI 10.1016/j.ajcnut.2026.101236; PMID 41687879. A double-blind randomised crossover controlled feeding study concerning plasma choline and betaine biomarkers.
10.1.3 Reasoning. The paper is cited in those pieces as a recent statement of the intake position, and the sentence attributed to it is one the paper does make.
10.1.4 Limitations. The statement is background framing in that paper, not its finding: it is a controlled feeding study about biomarkers, and it is not the source of a national intake estimate. The primary sources for the national figure are the survey analyses cited at clause 3.1.2, and that is where a reader checking the “9 in 10” figure should be sent.
10.2.1 Statement. The same piece states that only 10 per cent of a study population met the Adequate Intake for choline, citing Suzuki and colleagues.
10.2.2 Evidence. Suzuki A, Keller JE, Sullivan DK (2025), Journal of Food Composition and Analysis 148 Part 3:108484; DOI 10.1016/j.jfca.2025.108484; PMID 42389747. The abstract states that only 10 per cent of participants met the Adequate Intake for choline. The population is 203 adults aged 65 and over in the Midwestern United States, assessed by three-day food records.
10.2.3 Reasoning. The figure is quoted accurately and the study is real.
10.2.4 Limitations. It is not nationally representative and its population is not “American adults”: it is 203 older adults in one region, measured by food records. It cannot carry a national statement, and it is not the source of the figure at clauses 3.1 and 3.2, which rests on the national survey analyses at clause 3.1.2.
10.3.1 Statement. Pieces in the Journal state that “brain fog” draws about 60,500 United States searches a month.
10.3.2 Evidence. Google Keyword Planner, United States, retrieved August 2026. The figure is the tool's reported average monthly search volume for the matched term in that geography at that date.
10.3.3 Reasoning. The figure is offered as an indication of how often the phrase is looked up, and the tool and the month of retrieval are named so that the number is attributable to a source and a date rather than presented as a general fact.
10.3.4 Limitations. A keyword tool reports a rounded average of matched queries over a preceding period, not a count of people, not a count of sufferers, and not a measure of prevalence; one person may search many times and one search may match many terms. The figure is drawn from a commercial advertising tool and is not independently verifiable outside an account with access to it, so it does not meet the standard of the published sources cited elsewhere on this page, and nothing about the product rests on it.
10.4.1 Statement. Pieces in the Journal describe the amounts of alpha-GPC used in research in healthy adults.
10.4.2 Evidence. Single doses: 200 mg and 400 mg in twenty healthy adults, ten male and ten female, aged 22.0 ± 3.4 years (Parker 2015, clause 2.3.2); 315 mg and 630 mg in twenty resistance-trained men aged 20 to 55 (Kerksick 2024, clause 2.1.2). Daily dosing: 250 mg and 500 mg a day for seven days in forty-eight healthy college-aged males (Marcus 2017, clause 2.3.2). The published research in healthy adults therefore spans single doses of 200 mg to 630 mg and daily doses of 250 mg to 500 mg for a week.
10.4.3 Reasoning. The amounts are given so that a reader can place the 300 mg in this product against the amounts that have actually been studied, which is the only comparison that matters when the trials are few.
10.4.4 Limitations. Single-dose and daily-dose amounts must not be run together: the two largest amounts in the range, 315 mg and 630 mg, were single doses taken once at a study visit, not regimens taken daily, and the only daily-dosing arms ran for seven days. The floor of the range, 200 mg, comes from a conference proceedings abstract rather than a full peer-reviewed paper, and that study's result was null. No trial in healthy adults has dosed alpha-GPC daily for longer than a week.
10.5.1 Statement. Pieces in the Journal state that higher-dose alpha-GPC trials were conducted in people with diagnosed impairment, and are not a target for a healthy adult.
10.5.2 Evidence. De Jesus Moreno Moreno M (2003), cited at clause 8.1.2: choline alfoscerate 400 mg three times daily — 1,200 mg a day — for 180 days, in 261 patients with mild-to-moderate Alzheimer-type dementia aged 60 to 80, with efficacy measured at baseline, day 90 and day 180. Health Canada (2024), cited at clause 2.4.2, records 1,200 mg a day for up to six months as the ceiling of the human evidence. Separately, Sagaro GG, Amenta F (2025), Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis, Frontiers in Neurology 16:1649661; DOI 10.3389/fneur.2025.1649661, pools three randomised head-to-head trials, 358 randomised and 329 completers, in patients over fifty with multi-infarct or vascular dementia, and reports alpha-GPC superior to citicoline on a geriatric clinician rating scale (weighted mean difference −3.92; 95% confidence interval −7.41 to −0.42), with no significant difference on memory or word fluency; that review reports no doses, and is cited here for the comparison it makes, not for any amount.
10.5.3 Reasoning. Naming the dose and the population together is what keeps a clinical amount from being read as a recommendation: 1,200 mg a day was given to patients with dementia under supervision, and it is neither our amount nor a target for anyone buying a supplement.
10.5.4 Limitations. These are disease populations and disease endpoints, and nothing in them may be claimed for this product or for a healthy adult; the only use made of them on our site is to mark the boundary of the evidence. The head-to-head review is in patients with dementia, its instrument is a clinician rating scale rather than an attention test, and its effect is nowhere near a doubling — so it does not support the comparisons at clauses 2.1 to 2.3 and is not cited for them.
10.6.1 Statement. Two references that have circulated with these Journal pieces are not listed on this page: one for a narrative review of transport across the blood–brain barrier, and one for a null working-memory result with choline bitartrate.
10.6.2 Evidence. Neither could be resolved to a title, journal, volume and permanent identifier at the standard this page holds. An author-and-year with no identifier cannot be retrieved by a reader and is therefore not evidence.
10.6.3 Reasoning. The convention stated at clause 1.7 is that every source is printed with an identifier that allows independent retrieval. A reference that cannot meet it is recorded as absent rather than printed in a weaker form, because a citation nobody can follow is worse on a page of this kind than no citation.
10.6.4 Limitations. Nothing on this page rests on either reference, and no figure on the product page depends on them. Their absence here is not a statement that the underlying results do not exist; it is a statement that we cannot presently cite them to the standard the rest of this page uses. Clause 2.6 sets out what the record does establish about the passage of an oral choline dose, and clause 2.5 what it establishes about the comparison between choline forms.
11. Corrections
11.1 The clauses carrying the heaviest limitations are, in order of appearance: 2.1, 2.2 and 2.3, on the attention figure, its comparator and its plural framing; 2.4 and 2.5, on the superlatives applied to alpha-GPC as a form of choline; 2.7, on what reaches the brain; 2.8, on the sentence joining that superlative to a placebo-controlled measurement; 2.11, on caffeine adding nothing to the attention system; 2.13, on moving fat out of the liver; 4.2, on the beta-glucan and fruiting-body specification and the superlative attached to it; 4.4, on the foundation relationship between ingredients; 5.2, on the absence of jitters; 6.2 and 6.3, on the zinc intake fractions; 7.2, on the causal link between age-related absorption and our choice of methylcobalamin; 7.3, on the vitamin B12 fraction; 8.4, on the experiential lines of the timeline; 9.3, on the highest-quality formulation across all five ingredients; 9.5, on the scope of the laboratory report; 9.6, on the manufacturing standard; and 9.8, on the product-level statements about effect. A reader with limited time should read the fourth part of each of those clauses.
11.2 Where this page and any other page of ours describe the same figure differently, the source named here governs, and the clause that names it is the record. Where a source itself has been superseded — as two federal fact sheets cited here have been, at clauses 6.1.2 and 6.2.2 — the clause says what the earlier edition said, what the current edition says, and which of the two the wording on the site follows.
11.3 Corrections may be sent to hello@wealsupplements.com. A correction is assessed against the source named in the clause it concerns, and against the source the correspondent cites. Where it is sustained, the clause is amended to record what the source says, the date of the amendment is noted in the clause, and any figure on the site that the clause governs is reconsidered against the corrected record. Where it is not sustained, the reasoning is set out in reply. A correspondent who has supplied a correction that is sustained will be told what was changed.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.